Stroke Volume

• 

  Subject Areas on Research

  • "Protocol for a phase 2, randomized, double-blind, placebo-controlled, safety and efficacy study of dutogliptin in combination with filgrastim in early recovery post-myocardial infarction": study protocol for a randomized controlled trial. 
  • "Targeting the Heart" in Heart Failure: Myocardial Recovery in Heart Failure With Reduced Ejection Fraction. 
  • 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. 
  • 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. 
  • A Biomarker Approach to Understanding HFpEF. 
  • A Composite Score Summarizing Use and Dosing of Evidence-Based Medical Therapies in Heart Failure: A Nationwide Cohort Study. 
  • A Critical Evaluation of the Representation of Black Patients With Heart Failure and Preserved Ejection Fraction in Clinical Trials: A Literature Review. 
  • A Hospital and Postdischarge Quality Improvement Intervention and Outcomes and Care for Patients With Heart Failure With Reduced Ejection Fraction-Reply. 
  • A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator: The VICTORIA Trial. 
  • A Novel Rehabilitation Intervention for Older Patients With Acute Decompensated Heart Failure: The REHAB-HF Pilot Study. 
  • A QRS scoring system for assessing left ventricular function after myocardial infarction. 
  • A Randomized, Controlled Trial of Resistance Training Added to Caloric Restriction Plus Aerobic Exercise Training in Obese Heart Failure With Preserved Ejection Fraction. 
  • A bolus dose of 1.5 mg/kg amrinone effectively improves low cardiac output state following separation from cardiopulmonary bypass in cardiac surgical patients. 
  • A current and future outlook on upcoming technologies in remote monitoring of patients with heart failure. 
  • A genotype-directed comparative effectiveness trial of Bucindolol and metoprolol succinate for prevention of symptomatic atrial fibrillation/atrial flutter in patients with heart failure: Rationale and design of the GENETIC-AF trial. 
  • A mouse model of heart failure with preserved ejection fraction due to chronic infusion of a low subpressor dose of angiotensin II. 
  • A multicenter program for electronic health record screening for patients with heart failure with preserved ejection fraction: Lessons from the DELIVER-EHR initiative. 
  • A new in vivo method for quantitative analysis of stroke lesions using diffusion-weighted magnetic resonance microscopy. 
  • A noninvasive radiographic technique for evaluation of exercise-induced changes in cardiac function. 
  • A pooled analysis of coronary arterial patency and left ventricular function after intravenous thrombolysis for acute myocardial infarction. 
  • A prospective comparison of a noninvasive cardiac output monitor versus esophageal Doppler monitor for goal-directed fluid therapy in colorectal surgery patients. 
  • A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. 
  • Abi3bp regulates cardiac progenitor cell proliferation and differentiation. 
  • Accelerometer-Measured Daily Activity in Heart Failure With Preserved Ejection Fraction: Clinical Correlates and Association With Standard Heart Failure Severity Indices. 
  • Accuracy of left ventricular ejection fraction by contemporary multiple gated acquisition scanning in patients with cancer: comparison with cardiovascular magnetic resonance. 
  • Accuracy of three-dimensional echocardiography with unrestricted selection of imaging planes for measurement of left ventricular volumes and ejection fraction. 
  • Acquired dynamic left ventricular outflow tract obstruction complicating acute anterior myocardial infarction: serial echocardiographic and clinical evaluation. 
  • Acute Diuretic-Sparing Effects of Sacubitril-Valsartan: Staying in the Loop. 
  • Acute Echocardiographic Effects of Exogenous Ketone Administration in Healthy Participants. 
  • Acute Hemodynamic Effects and Tolerability of Phosphodiesterase-1 Inhibition With ITI-214 in Human Systolic Heart Failure. 
  • Acute Ischemic Stroke, Depressed Left Ventricular Ejection Fraction, and Sinus Rhythm: Prevalence and Practice Patterns. 
  • Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure: The ATOMIC-AHF Study. 
  • Acute and long-term efficacy and safety of catheter cryoablation of the cavotricuspid isthmus for treatment of type 1 atrial flutter. 
  • Acute functional consequences of left ventriculotomy. 
  • Acute heart failure associated with high admission blood pressure--a distinct vascular disorder? 
  • Acute heart failure in the young: Clinical characteristics and biomarker profiles. 
  • Adaptive servo-ventilation reduces atrial fibrillation burden in patients with heart failure and sleep apnea. 
  • Adding Troponin to the Puzzle of Heart Failure With Preserved Ejection Fraction: Marker or Mediator? 
  • Adiposity and Incident Heart Failure and its Subtypes: MESA (Multi-Ethnic Study of Atherosclerosis). 
  • Adoption of Sacubitril/Valsartan Among Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The Get With The Guidelines-Heart Failure Registry. 
  • Advanced heart failure patients supported with ambulatory inotropic therapy: What defines success of therapy? 
  • Advanced heart failure treated with continuous-flow left ventricular assist device. 
  • Adverse Renal Response to Decongestion in the Obese Phenotype of Heart Failure With Preserved Ejection Fraction. 
  • Aerobic exercise training and general health status in ambulatory heart failure patients with a reduced ejection fraction-Findings from the Heart Failure and A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION)trial. 
  • African American-Caucasian American differences in aortic valve replacement in patients with severe aortic stenosis. 
  • Age Differences in Effects of Sacubitril/Valsartan on Cardiac Remodeling, Biomarkers, and Health Status. 
  • Age-Related Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction. 
  • Age-Related Divergence of Risk-Benefit Relationship of Spironolactone Treatment for Heart Failure With Preserved Ejection Fraction. 
  • Albuminuria in chronic heart failure: prevalence and prognostic importance. 
  • Alcohol septal ablation for the treatment of hypertrophic obstructive cardiomyopathy. A multicenter North American registry. 
  • Aldosterone: Behind the Scenes of Depression and Heart Failure? 
  • All rise! Orthostatic hypotension in heart failure. Letter regarding the article 'Management of low blood pressure in ambulatory heart failure with reduced ejection fraction patients'. 
  • Alterations in hemodynamics and left ventricular contractility during carbon dioxide pneumoperitoneum. 
  • Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. 
  • Analysis of Regional Left Ventricular Strain in Patients with Chagas Disease and Normal Left Ventricular Systolic Function. 
  • Anatomic validation of a novel method for left ventricular volume and mass measurements with use of real-time 3-dimensional echocardiography. 
  • Anemia in patients with heart failure and preserved systolic function. 
  • Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction. 
  • Angiotensin receptor neprilysin inhibition in heart failure: mechanistic action and clinical impact. 
  • Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure. 
  • Antidepressant use, depression, and survival in patients with heart failure. 
  • Aortic valve replacement for aortic stenosis in patients with left ventricular dysfunction. 
  • Aortocoronary bypass grafting in patients without left main stenosis. Relation of risk factors to early and late survival. 
  • Apolipoprotein E polymorphisms and age at first coronary artery bypass graft. 
  • Applicability of Vericiguat to Patients Hospitalized for Heart Failure in the United States. 
  • Application of Diagnostic Algorithms for Heart Failure With Preserved Ejection Fraction to the Community. 
  • Are We Approaching Chronotropy (In)competently? 
  • Are existing and emerging biomarkers associated with cardiorespiratory fitness in patients with chronic heart failure? 
  • Aspiration thrombectomy in ST-Elevation myocardial infarction: Further insights from a network meta-analysis of randomized trials. 
  • Assessing race and ethnicity differences in outcomes based on GDMT and target NT-proBNP in patients with heart failure with reduced ejection fraction: An analysis of the GUIDE-IT study. 
  • Assessment of Biomarkers of Myocardial injury, Inflammation, and Renal Function in Heart Failure With Reduced Ejection Fraction: The VICTORIA Biomarker Substudy. 
  • Assessment of Diastolic Function in Single-Ventricle Patients After the Fontan Procedure. 
  • Assessment of ECG during hybrid comprehensive telerehabilitation in heart failure patients-Subanalysis of the Telerehabilitation in Heart Failure Patients (TELEREH-HF) randomized clinical trial. 
  • Assessment of Limitations to Optimization of Guideline-Directed Medical Therapy in Heart Failure From the GUIDE-IT Trial: A Secondary Analysis of a Randomized Clinical Trial. 
  • Assessment of Omecamtiv Mecarbil for the Treatment of Patients With Severe Heart Failure: A Post Hoc Analysis of Data From the GALACTIC-HF Randomized Clinical Trial. 
  • Assessment of cardiac allograft systolic function by global longitudinal strain: From donor to recipient. 
  • Assessment of left ventricular functional preservation during isolated cardiac valve operations. 
  • Assessment of left ventricular pressure-volume relations using gated radionuclide angiography, echocardiography, and micromanometer pressure recordings. A new method for serial measurements of systolic and diastolic function in man. 
  • Assessment of myocardial scarring improves risk stratification in patients evaluated for cardiac defibrillator implantation. 
  • Assessment of regional left ventricular function using gated radionuclide angiography. 
  • Assessment of the Frank-Starling relationship by two-dimensional echocardiography. 
  • Association Between Angiotensin Receptor-Neprilysin Inhibition, Cardiovascular Biomarkers, and Cardiac Remodeling in Heart Failure With Reduced Ejection Fraction. 
  • Association Between Comorbidities and Outcomes in Heart Failure Patients With and Without an Implantable Cardioverter-Defibrillator for Primary Prevention. 
  • Association Between Early Left Ventricular Ejection Fraction Improvement After Transcatheter Aortic Valve Replacement and 5-Year Clinical Outcomes. 
  • Association Between Sacubitril/Valsartan Initiation and Health Status Outcomes in Heart Failure With Reduced Ejection Fraction. 
  • Association Between Sacubitril/Valsartan Initiation and Mitral Regurgitation Severity in Heart Failure With Reduced Ejection Fraction: The PROVE-HF Study. 
  • Association between beta-blocker use and mortality/morbidity in older patients with heart failure with reduced ejection fraction. A propensity score-matched analysis from the Swedish Heart Failure Registry. 
  • Association between body surface area and prescribed doses of guideline-directed medications among international patients with heart failure and reduced ejection fraction. 
  • Association between left ventricular ejection fraction post-cardiac resynchronization treatment and subsequent implantable cardioverter defibrillator therapy for sustained ventricular tachyarrhythmias. 
  • Association between levosimendan, postoperative AKI, and mortality in cardiac surgery: Insights from the LEVO-CTS trial. 
  • Association between myocardial substrate, implantable cardioverter defibrillator shocks and mortality in MADIT-CRT. 
  • Association between potassium level and outcomes in heart failure with reduced ejection fraction: a cohort study from the Swedish Heart Failure Registry. 
  • Association between systolic ejection time and outcomes in heart failure by ejection fraction. 
  • Association of Dapagliflozin Use With Clinical Outcomes and the Introduction of Uric Acid-Lowering Therapy and Colchicine in Patients With Heart Failure With and Without Gout: A Patient-Level Pooled Meta-analysis of DAPA-HF and DELIVER. 
  • Association of Estimated Sodium Intake With Adverse Cardiac Structure and Function: From the HyperGEN Study. 
  • Association of Feature-Tracking Cardiac Magnetic Resonance Imaging Left Ventricular Global Longitudinal Strain With All-Cause Mortality in Patients With Reduced Left Ventricular Ejection Fraction. 
  • Association of Left Atrial Structure and Function With Heart Failure in Older Adults. 
  • Association of US Centers for Medicare and Medicaid Services Hospital 30-Day Risk-Standardized Readmission Metric With Care Quality and Outcomes After Acute Myocardial Infarction: Findings From the National Cardiovascular Data Registry/Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With the Guidelines. 
  • Association of Visit-to-Visit Variability in Kidney Function and Serum Electrolyte Indexes With Risk of Adverse Clinical Outcomes Among Patients With Heart Failure With Preserved Ejection Fraction. 
  • Association of arginine vasopressin levels with outcomes and the effect of V2 blockade in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. 
  • Association of comorbidity burden with abnormal cardiac mechanics: findings from the HyperGEN study. 
  • Association of depressive symptoms with reduced baroreflex cardiac control in coronary artery disease. 
  • Association of hospital myocardial infarction volume with adherence to American College of Cardiology/American Heart Association performance measures: Insights from the National Cardiovascular Data Registry. 
  • Association of left ventricular ejection fraction with worsening renal function in patients with acute heart failure: insights from the RELAX-AHF-2 study. 
  • Association of liver fibrosis risk scores with clinical outcomes in patients with heart failure with preserved ejection fraction: findings from TOPCAT. 
  • Association of low-grade albuminuria with adverse cardiac mechanics: findings from the hypertension genetic epidemiology network (HyperGEN) study. 
  • Association of novel biomarkers of cardiovascular stress with left ventricular hypertrophy and dysfunction: implications for screening. 
  • Association of physical fitness and transient myocardial ischemia in patients with coronary artery disease. 
  • Association of prolonged QRS duration with ventricular tachyarrhythmias and sudden cardiac death in the Multicenter Automatic Defibrillator Implantation Trial II (MADIT-II). 
  • Association of serum triiodothyronine with B-type natriuretic peptide and severe left ventricular diastolic dysfunction in heart failure with preserved ejection fraction. 
  • Association of the Novel Inflammatory Marker GlycA and Incident Heart Failure and Its Subtypes of Preserved and Reduced Ejection Fraction: The Multi-Ethnic Study of Atherosclerosis. 
  • Association of the frontal QRS-T angle with adverse cardiac remodeling, impaired left and right ventricular function, and worse outcomes in heart failure with preserved ejection fraction. 
  • Associations between Cardiac Magnetic Resonance T1 Mapping Parameters and Ventricular Arrhythmia in Patients with Chagas Disease. 
  • Associations between aldosterone antagonist therapy and risks of mortality and readmission among patients with heart failure and reduced ejection fraction. 
  • Associations between atrial fibrillation and early outcomes of patients with heart failure and reduced or preserved ejection fraction. 
  • Atrial Fibrillation and Dapagliflozin Efficacy in Patients With Preserved or Mildly Reduced Ejection Fraction. 
  • Atrial Natriuretic Peptide and Treatment With Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction. 
  • Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. 
  • Atrial fibrillation in heart failure: what should we do? 
  • Atrial fibrillation is an independent risk factor for heart failure hospitalization in heart failure with preserved ejection fraction. 
  • Atrial fibrillation or flutter on initial electrocardiogram is associated with worse outcomes in patients admitted for worsening heart failure with reduced ejection fraction: findings from the EVEREST Trial. 
  • Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): a randomised, multicentre, blinded, sham-controlled trial. 
  • Augmentation of mortality risk discriminating power of left ventricular ejection fraction by measures of nonuniformity in systolic emptying on radionuclide ventriculography. 
  • Axial Muscle Size as a Strong Predictor of Death in Subjects With and Without Heart Failure. 
  • B-type natriuretic peptide assessment in ambulatory heart failure patients: insights from IMPROVE HF. 
  • Baroreflex activation therapy with the Barostim™ device in patients with heart failure with reduced ejection fraction: a patient level meta-analysis of randomized controlled trials. 
  • Baseline Characteristics Predict the Presence of Amyloid on Endomyocardial Biopsy. 
  • Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction: DELIVER Trial. 
  • Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial. 
  • Baseline metabolomic profiles predict cardiovascular events in patients at risk for coronary artery disease. 
  • Benefit of cardiopoietic mesenchymal stem cell therapy on left ventricular remodelling: results from the Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) study. 
  • Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programme. 
  • Beta-Blockers for Primary Therapy of Heart Failure With Preserved Ejection Fraction: An Idea Whose Time Has Gone? 
  • Beta-blocker and ACE-inhibitor dosing as a function of body surface area: From the HF-ACTION trial. 
  • Beta1-adrenergic receptors stimulate cardiac contractility and CaMKII activation in vivo and enhance cardiac dysfunction following myocardial infarction. 
  • Biomarker Profile of Left Atrial Myopathy in Heart Failure With Preserved Ejection Fraction: Insights From the RELAX Trial. 
  • Biomarker Profiles of Acute Heart Failure Patients With a Mid-Range Ejection Fraction. 
  • Biomarkers and heart failure events in patients with atrial fibrillation in the ARISTOTLE trial evaluated by a multi-state model. 
  • Biomarkers in acutely decompensated heart failure with preserved or reduced ejection fraction. 
  • Blood Pressure and Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: DELIVER. 
  • Blood Pressure and Safety Events With Vericiguat in the VICTORIA Trial. 
  • Blood pressure reactivity to psychological stress is associated with clinical outcomes in patients with heart failure. 
  • Blunted cyclic variation of heart rate predicts mortality risk in post-myocardial infarction, end-stage renal disease, and chronic heart failure patients. 
  • Body Composition, Natriuretic Peptides, and Adverse Outcomes in Heart Failure With Preserved and Reduced Ejection Fraction. 
  • Body surface area and medication dosing in patients with heart failure with reduced ejection fraction. 
  • Brain Natriuretic Peptide Treatment and Heart Failure Prevention: Reliving the Mistakes of the Past or Charting a New Course for the Future? 
  • Brain and central haemodynamics and oxygenation during maximal exercise in humans. 
  • Brain death further promotes ischemic reperfusion injury of the rabbit myocardium. 
  • Bridge to long-term mechanical circulatory support with a left ventricular assist device: novel use of transcatheter aortic valve replacement. 
  • Bucindolol for the Maintenance of Sinus Rhythm in a Genotype-Defined HF Population: The GENETIC-AF Trial. 
  • Building the Foundation for a New Era of Quadruple Therapy in Heart Failure. 
  • Building the case for aerobic exercise in ambulatory patients with heart failure and a reduced ejection fraction. 
  • Burden of medical co-morbidities and benefit from surgical revascularization in patients with ischaemic cardiomyopathy. 
  • CABG Improves Outcomes in Patients With Ischemic Cardiomyopathy: 10-Year Follow-Up of the STICH Trial. 
  • CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation, SGLT2 Inhibitors, ARNI in HFpEF, and Tafamidis in Amyloidosis. 
  • CYP3A4 genotype is associated with sildenafil concentrations in patients with heart failure with preserved ejection fraction. 
  • Can catheter ablation of atrial fibrillation reverse heart failure with preserved ejection fraction? 
  • Can walking patients with heart failure and preserved ejection fraction tell us who should walk also to the catheterization laboratory or just walk home? 
  • Candesartan in heart failure--assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm-Programme Investigators. 
  • Capillary density of skeletal muscle: a contributing mechanism for exercise intolerance in class II-III chronic heart failure independent of other peripheral alterations. 
  • Cardiac I-1c overexpression with reengineered AAV improves cardiac function in swine ischemic heart failure. 
  • Cardiac Magnetic Resonance Feature Tracking Global Longitudinal Strain and Prognosis After Heart Transplantation. 
  • Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure. 
  • Cardiac Pressure-Volume Loop Analysis Using Conductance Catheters in Mice. 
  • Cardiac computed tomographic angiography what's the prognosis? 
  • Cardiac conduction system disease after transcatheter aortic valve replacement. 
  • Cardiac ejection fraction: phantom study comparing cine MR imaging, radionuclide blood pool imaging, and ventriculography. 
  • Cardiac evaluation for structural abnormalities may not be required in patients presenting with syncope and a normal ECG result in an observation unit setting. 
  • Cardiac evaluation of mitoxantrone. 
  • Cardiac function in alcohol-associated systemic hypertension. 
  • Cardiac mechanics: basic and clinical contemporary research. 
  • Cardiac output by impedance cardiography: two alternative methodologies compared with thermodilution. 
  • Cardiac resynchronization therapy in chronic heart failure with moderately reduced left ventricular ejection fraction: Lessons from the Multicenter InSync Randomized Clinical Evaluation MIRACLE EF study. 
  • Cardiac resynchronization therapy in heart failure patients with less severe left ventricular dysfunction. 
  • Cardiac transplantation in a pediatric patient with systemic sclerosis. 
  • Cardiac troponin I for prediction of clinical outcomes and cardiac function through 3-month follow-up after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. 
  • Cardiac troponin T and I, echocardiographic [correction of electrocardiographic] wall motion analyses, and ejection fractions in athletes participating in the Hawaii Ironman Triathlon. 
  • Cardiac-resynchronization therapy for the prevention of heart-failure events. 
  • Cardioprotective and antiapoptotic effects of heme oxygenase-1 in the failing heart. 
  • Cardiorespiratory coupling in cetaceans; a physiological strategy to improve gas exchange? 
  • Cardiothoracic Morphology Measures in Heart Failure Patients to Inform Device Designs. 
  • Cardiovascular Function in Long-Term Hematopoietic Cell Transplantation Survivors. 
  • Cardiovascular magnetic resonance imaging in suspected cardiac tumour: a multicentre outcomes study. 
  • Cardiovascular phenotype in HFpEF patients with or without diabetes: a RELAX trial ancillary study. 
  • Care Optimization Through Patient and Hospital Engagement Clinical Trial for Heart Failure: Rationale and design of CONNECT-HF. 
  • Care and outcomes of Hispanic patients admitted with heart failure with preserved or reduced ejection fraction: findings from get with the guidelines-heart failure. 
  • Catheter ablation of atrial fibrillation in patients with heart failure and preserved ejection fraction. 
  • Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) program. 
  • Central venous pressure after coronary artery bypass surgery: does it predict postoperative mortality or renal failure? 
  • Change Is Not Always Good. 
  • Changes in Dyspnea Status During Hospitalization and Postdischarge Health-Related Quality of Life in Patients Hospitalized for Heart Failure: Findings From the EVEREST Trial. 
  • Changes in left ventricular systolic performance immediately after percutaneous aortic balloon valvuloplasty. 
  • Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction After a Recent Worsening Heart Failure Event. 
  • Characteristics and Treatments of Patients Enrolled in the CHAMP-HF Registry Compared With Patients Enrolled in the PARADIGM-HF Trial. 
  • Characteristics and clinical outcomes of patients with acute heart failure with a supranormal left ventricular ejection fraction. 
  • Characteristics of sepsis-induced cardiac dysfunction using speckle-tracking echocardiography: a feasibility study. 
  • Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. 
  • Characterization of health-related quality of life in heart failure patients with preserved versus low ejection fraction in CHARM. 
  • Characterization of heart failure patients with preserved ejection fraction: a comparison between ADHERE-US registry and ADHERE-International registry. 
  • Characterization of the Obese Phenotype of Heart Failure With Preserved Ejection Fraction: A RELAX Trial Ancillary Study. 
  • Characterization of the Progression From Ambulatory to Hospitalized Heart Failure With Preserved Ejection Fraction. 
  • Children with sick hearts: towards anesthesia safety. 
  • Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial. 
  • Chronic Total Occlusion Trials: A Step in the Right Direction. 
  • Chronic exposure to nicotine does not prevent neurocognitive decline after cardiac surgery. 
  • Cine MR determination of left ventricular ejection fraction. 
  • Circulating Cardiac Troponin I Levels Measured by a Novel Highly Sensitive Assay in Acute Decompensated Heart Failure: Insights From the ASCEND-HF Trial. 
  • Circulating Neprilysin in Patients With Heart Failure and Preserved Ejection Fraction. 
  • Citius, altius, fortius (the Olympic motto: swifter, higher, stronger). 
  • Classifying heart failure based on ejection fraction: imperfect but enduring. 
  • Clinical Effectiveness of Hydralazine-Isosorbide Dinitrate Therapy in Patients With Heart Failure and Reduced Ejection Fraction: Findings From the Get With The Guidelines-Heart Failure Registry. 
  • Clinical Effectiveness of Sacubitril/Valsartan Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction. 
  • Clinical Outcomes Using Freestyle Valve-Valsalva Graft Composite Conduit for Aortic Root Replacement. 
  • Clinical Outcomes With Metformin and Sulfonylurea Therapies Among Patients With Heart Failure and Diabetes. 
  • Clinical Outcomes and Response to Vericiguat According to Index Heart Failure Event: Insights From the VICTORIA Trial. 
  • Clinical Outcomes in Different Types of Aortic Stenosis as Assessed by Doppler Echocardiography. 
  • Clinical Outcomes in Patients With ST-Segment Elevation MI and No Standard Modifiable Cardiovascular Risk Factors. 
  • Clinical Profile, Health Care Costs, and Outcomes of Patients Hospitalized for Heart Failure With Severely Reduced Ejection Fraction. 
  • Clinical and Echocardiographic Characteristics of Patients Hospitalized With Acute Versus Chronic Heart Failure With Preserved Ejection Fraction (From the ARIC Study). 
  • Clinical and angiographic correlates of short- and long-term mortality in patients undergoing coronary artery bypass grafting. 
  • Clinical and angiographic predictors of short- and long-term ischemic events in acute coronary syndromes: results from the Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial. 
  • Clinical and economic implications of the Multicenter Automatic Defibrillator Implantation Trial-II. 
  • Clinical application of cine-MRI in the visual assessment of mitral regurgitation compared to echocardiography and cardiac catheterization. 
  • Clinical assessment of ventricular ejection dynamics with and without outflow obstruction. 
  • Clinical characteristics and outcomes of patients with and without diabetes in the Surgical Treatment for Ischemic Heart Failure (STICH) trial. 
  • Clinical characteristics and outcomes of patients with angina and heart failure in the CHARM (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) Programme. 
  • Clinical characteristics and outcomes of young and very young adults with heart failure: The CHARM programme (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity). 
  • Clinical characteristics, response to exercise training, and outcomes in patients with heart failure and chronic obstructive pulmonary disease: findings from Heart Failure and A Controlled Trial Investigating Outcomes of Exercise TraiNing (HF-ACTION). 
  • Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program. 
  • Clinical correlates and heritability of cardiac mechanics: The HyperGEN study. 
  • Clinical determinants of mortality in patients with angiographically diagnosed ischemic or nonischemic cardiomyopathy. 
  • Clinical effectiveness of CRT and ICD therapy in heart failure patients by racial/ethnic classification: insights from the IMPROVE HF registry. 
  • Clinical effectiveness of cardiac resynchronization and implantable cardioverter-defibrillator therapy in men and women with heart failure: findings from IMPROVE HF. 
  • Clinical effects of methamphetamine vapor inhalation. 
  • Clinical factors related to morbidity and mortality in high-risk heart failure patients: the GUIDE-IT predictive model and risk score. 
  • Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) programme. 
  • Clinical outcomes according to baseline blood pressure in patients with a low ejection fraction in the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) Program. 
  • Clinical outcomes in patients on beta-blocker therapy admitted with worsening chronic heart failure. 
  • Clinical pathway to screen for cardiac amyloidosis in heart failure with preserved ejection fraction. 
  • Clinical predictors and hemodynamic consequences of elevated peripheral chemosensitivity in optimally treated men with chronic systolic heart failure. 
  • Clinical profile and prognostic value of anemia at the time of admission and discharge among patients hospitalized for heart failure with reduced ejection fraction: findings from the EVEREST trial. 
  • Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial. 
  • Clinical trajectory of patients with a worsening heart failure event and reduced ventricular ejection fraction. 
  • Clinical trials in Japan and the United States. 
  • Combating Acute Heart Failure in the Arena: Lessons From the ROPA-DOP Trial. 
  • Combined Tc-99m sestamibi first-pass radionuclide angiography and cardiac SPECT imaging during arbutamine infusion delivered by a computerized closed-loop system. 
  • Combined neprilysin and renin-angiotensin system inhibition in heart failure with reduced ejection fraction: a meta-analysis. 
  • Combined tissue-type plasminogen activator and prostacyclin therapy for acute myocardial infarction. Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 4 Study Group. 
  • Commentary: Shouldering ever heavier burdens: Aortic root replacement in the context of depressed left ventricular ejection fraction. 
  • Comparative Effectiveness of Dosing of Medical Therapy for Heart Failure: From the CHAMP-HF Registry. 
  • Comparative Effectiveness of Implantable Cardioverter Defibrillators for Primary Prevention in Women. 
  • Comparative Effectiveness of Primary Prevention Implantable Cardioverter-Defibrillators in Older Heart Failure Patients With Diabetes Mellitus. 
  • Comparative early and late outcomes after primary percutaneous coronary intervention in ST-segment elevation and non-ST-segment elevation acute myocardial infarction (from the CADILLAC trial). 
  • Comparative effectiveness of cardiac resynchronization therapy with an implantable cardioverter-defibrillator versus defibrillator therapy alone: a cohort study. 
  • Comparison of Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction With Versus Without Hyperuricemia or Gout. 
  • Comparison of ECG-gated rectilinear vs. real-time radial K-space sampling schemes in cine True-FISP cardiac MRI. 
  • Comparison of Fontan survivors with and without pacemakers: a report from the Pediatric Heart Network Fontan Cross-Sectional Study. 
  • Comparison of Frequency of Frailty and Severely Impaired Physical Function in Patients ≥60 Years Hospitalized With Acute Decompensated Heart Failure Versus Chronic Stable Heart Failure With Reduced and Preserved Left Ventricular Ejection Fraction. 
  • Comparison of Hydralazine/Nitrate and Angiotensin Receptor Neprilysin Inhibitor Use Among Black Versus Nonblack Americans With Heart Failure and Reduced Ejection Fraction (from CHAMP-HF). 
  • Comparison of New York Heart Association Class and Patient-Reported Outcomes for Heart Failure With Reduced Ejection Fraction. 
  • Comparison of clinical characteristics, treatments and outcomes of patients with ST-elevation acute myocardial infarction with versus without new or presumed new left bundle branch block (from NCDR®). 
  • Comparison of echocardiographic and cardiac magnetic resonance imaging measurements of functional single ventricular volumes, mass, and ejection fraction (from the Pediatric Heart Network Fontan Cross-Sectional Study). 
  • Comparison of high- and low-intensity exercise training early after acute myocardial infarction. 
  • Comparison of high-dose and medium-dose propranolol in the relief of exercise-induced myocardial ischemia. 
  • Comparison of impedance cardiographic measurements using band and spot electrodes. 
  • Comparison of long-term postoperative sequelae in patients with tetralogy of Fallot versus isolated pulmonic stenosis. 
  • Comparison of magnetic resonance feature tracking for strain calculation with harmonic phase imaging analysis. 
  • Comparison of medical therapy dosing in outpatients cared for in cardiology practices with heart failure and reduced ejection fraction with and without device therapy: report from IMPROVE HF. 
  • Comparison of medicine alone, coronary angioplasty, and left internal mammary artery-coronary artery bypass for one-vessel proximal left anterior descending coronary artery disease. 
  • Comparison of preload recruitable stroke work, end-systolic pressure-volume and dP/dtmax-end-diastolic volume relations as indexes of left ventricular contractile performance in patients undergoing routine cardiac catheterization. 
  • Comparison of right and left ventricular function and size in Duchenne muscular dystrophy. 
  • Comparison of survival after mitral valve replacement with biologic and mechanical valves in 1139 patients. 
  • Comparison of the relation between left ventricular anatomy and QRS duration in patients with cardiomyopathy with versus without left bundle branch block. 
  • Comparison of time domain and frequency domain variables from the signal-averaged electrocardiogram: a multivariable analysis. 
  • Comparison of usefulness of N-terminal pro-brain natriuretic peptide as an independent predictor of cardiac function among admission cardiac serum biomarkers in patients with anterior wall versus nonanterior wall ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. 
  • Complementarity and competitiveness of the intrinsic and extrinsic components of the total ventricular load: demonstration after valve replacement in aortic stenosis. 
  • Complete atrioventricular cardiac transplantation: improved performance compared with the standard technique. 
  • Complications and Mortality Following CRT-D Versus ICD Implants in Older Medicare Beneficiaries With Heart Failure. 
  • Computational fluid dynamics of left ventricular ejection. 
  • Computer-assisted quantification of myocardial reperfusion after primary percutaneous coronary intervention predicts functional and contrast-enhanced cardiovascular magnetic resonance outcomes in patients with ST-segment elevation myocardial infarction. 
  • Contemporary Applications of Machine Learning for Device Therapy in Heart Failure. 
  • Contemporary Treatment Patterns and Clinical Outcomes of Comorbid Diabetes Mellitus and HFrEF: The CHAMP-HF Registry. 
  • Contemporary outpatient management of patients with worsening heart failure with reduced ejection fraction: Rationale and design of the CHART-HF study. 
  • Contemporary utilization and outcomes of intra-aortic balloon counterpulsation in acute myocardial infarction: the benchmark registry. 
  • Contextualizing Risk Among Patients With Heart Failure. 
  • Continuous versus bolus dosing of Furosemide for patients hospitalized for heart failure. 
  • Contrast-enhanced anatomic imaging as compared to contrast-enhanced tissue characterization for detection of left ventricular thrombus. 
  • Contribution of afterload, hypertrophy and geometry to left ventricular ejection fraction in aortic valve stenosis, pure aortic regurgitation and idiopathic dilated cardiomyopathy. 
  • Contribution of cardiac and extra-cardiac disease burden to risk of cardiovascular outcomes varies by ejection fraction in heart failure. 
  • Core lab analysis of baseline echocardiographic studies in the STICH trial and recommendation for use of echocardiography in future clinical trials. 
  • Coronary artery bypass in patients with severely depressed ventricular function. 
  • Coronary bypass surgery with or without surgical ventricular reconstruction. 
  • Coronary revascularization rather than cardiac transplantation for chronic ischemic cardiomyopathy. 
  • Coronary-Artery Bypass Surgery in Patients with Ischemic Cardiomyopathy. 
  • Correlation of Impedance Cardiography-Derived and Cardiac Magnetic Resonance-Derived Stroke Volumes. 
  • Correlations between physician-perceived functional status, patient-perceived health status, and cardiopulmonary exercise results in hypertrophic cardiomyopathy. 
  • Cost-Effectiveness of Coronary Artery Bypass Surgery Versus Medicine in Ischemic Cardiomyopathy: The STICH Randomized Clinical Trial. 
  • Costs for heart failure with normal vs reduced ejection fraction. 
  • Current concepts of fluid management in enhanced recovery pathways. 
  • Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial. 
  • Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER. 
  • Dapagliflozin and New York Heart Association functional class in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial. 
  • Dapagliflozin for heart failure according to body mass index: the DELIVER trial. 
  • Dapagliflozin in Black and White Patients With Heart Failure Across the Ejection Fraction Spectrum. 
  • Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. 
  • Dapagliflozin in Patients Recently Hospitalized With Heart Failure and Mildly Reduced or Preserved Ejection Fraction. 
  • Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial. 
  • Dapagliflozin in patients with heart failure with mildly reduced and preserved ejection fraction treated with a mineralocorticoid receptor antagonist or sacubitril/valsartan. 
  • Deciding Whether to Take Sacubitril/Valsartan: How Cardiologists and Patients Discuss Out-of-Pocket Costs. 
  • Declining Risk of Sudden Death in Heart Failure. 
  • Defibrillation causes immediate cardiac dilation in humans. 
  • Depression and increased myocardial ischemic activity in patients with ischemic heart disease. 
  • Depression: are we ignoring an important comorbidity in heart failure? 
  • Design Elements and Enrollment Patterns of Contemporary Trials in Heart Failure With Preserved Ejection Fraction: A Systematic Review. 
  • Design and rationale of the PROTECT study: a placebo-controlled randomized study of the selective A1 adenosine receptor antagonist rolofylline for patients hospitalized with acute decompensated heart failure and volume overload to assess treatment effect on congestion and renal function. 
  • Design of the RELAXin in acute heart failure study. 
  • Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): a Phase III, anaemia correction, morbidity-mortality trial. 
  • Designation and distribution of events in the Multicenter UnSustained Tachycardia Trial (MUSTT). 
  • Detection of myocardial damage in patients with sarcoidosis. 
  • Detection, characterization and functional assessment of reperfused Q-wave acute myocardial infarction by cine magnetic resonance imaging. 
  • Determinants of one-year outcome from balloon aortic valvuloplasty. 
  • Determinants of variable exercise performance among patients with severe left ventricular dysfunction. 
  • Developing and validating models to predict sudden death and pump failure death in patients with heart failure and preserved ejection fraction. 
  • Developing therapies for heart failure with preserved ejection fraction: current state and future directions. 
  • Development and validation of a risk model for in-hospital worsening heart failure from the Acute Decompensated Heart Failure National Registry (ADHERE). 
  • Developments in Exercise Capacity Assessment in Heart Failure Clinical Trials and the Rationale for the Design of METEORIC-HF. 
  • Device Therapy for Heart Failure with Preserved Ejection Fraction. 
  • Diagnosing heart failure with preserved ejection fraction in 2019: the search for a gold standard. 
  • Diagnostic usefulness and prognostic implications of the mitral E/E' ratio in patients with heart failure and severe secondary mitral regurgitation. 
  • Diastolic Dysfunction in Individuals With Human Immunodeficiency Virus Infection: Literature Review, Rationale and Design of the Characterizing Heart Function on Antiretroviral Therapy (CHART) Study. 
  • Diastolic Function in Heart Failure With Reduced Ejection Fraction: The Overlooked Prognosticator? 
  • Differences Between Patients Enrolled Early and Late During Clinical Trial Recruitment: Insights From the HF-ACTION Trial. 
  • Differences in NT-proBNP Response and Prognosis in Men and Women With Heart Failure With Reduced Ejection Fraction. 
  • Differences in skeletal muscle between men and women with chronic heart failure. 
  • Different effects of prolonged exercise on the right and left ventricles. 
  • Differential Response to Low-Dose Dopamine or Low-Dose Nesiritide in Acute Heart Failure With Reduced or Preserved Ejection Fraction: Results From the ROSE AHF Trial (Renal Optimization Strategies Evaluation in Acute Heart Failure). 
  • Differential ventricular ischemic injury: an experimental model of right ventricular failure with a variable degree of left ventricular dysfunction. 
  • Diminishment of respiratory sinus arrhythmia foreshadows doxorubicin-induced cardiomyopathy. 
  • Discordance of Pressure and Volume: Potential Implications for Pressure-Guided Remote Monitoring in Heart Failure. 
  • Discriminating clinical features of heart failure with preserved vs. reduced ejection fraction in the community. 
  • Disproportionate effects of regional hypokinesis on radionuclide ejection fraction: compensation using attenuation-corrected ventricular volumes. 
  • Dissociation between global and regional systolic and diastolic ventricular function during coronary occlusion and reperfusion. 
  • Dissociation between hemodynamic changes and symptom improvement in patients with advanced congestive heart failure. 
  • Diuretic Changes, Health Care Resource Utilization, and Clinical Outcomes for Heart Failure With Reduced Ejection Fraction: From the Change the Management of Patients With Heart Failure Registry. 
  • Do patients with a left ventricular ejection fraction between 30% and 35% benefit from a primary prevention implantable cardioverter defibrillator? 
  • Does heart failure etiology, New York Heart Association class, or ejection fraction affect the ability of clopidogrel to inhibit heightened platelet activity? 
  • Does hypotension during dobutamine stress echocardiography correlate with anatomic or functional cardiac impairment? 
  • Does initial shunt type for the Norwood procedure affect echocardiographic measures of cardiac size and function during infancy?: the Single Vventricle Reconstruction trial. 
  • Does myocardial perfusion imaging provide incremental prognostic information to left ventricular ejection fraction? 
  • Does preoperative atrial fibrillation increase the risk for mortality and morbidity after coronary artery bypass grafting? 
  • Does prior coronary angioplasty affect outcomes of surgical coronary revascularization? Insights from the STICH trial. 
  • Does the Implantable Cardioverter-Defibrillator Benefit Vary With the Estimated Proportional Risk of Sudden Death in Heart Failure Patients? 
  • Does transendocardial injection of mesenchymal stem cells improve myocardial function locally or globally?: An analysis from the Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis (POSEIDON) randomized trial. 
  • Dose of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and Outcomes in Heart Failure: A Meta-Analysis. 
  • Dose-Blinded Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Outcomes Through 32 Weeks. 
  • Dose-Response to Sacubitril/Valsartan in Patients With Heart Failure and Reduced Ejection Fraction. 
  • Dosing of beta-blocker therapy before, during, and after hospitalization for heart failure (from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure). 
  • Dronedarone for the treatment of atrial fibrillation with concomitant heart failure with preserved and mildly reduced ejection fraction: a post-hoc analysis of the ATHENA trial. 
  • Drug Development for Heart Failure With Preserved Ejection Fraction: What Pieces Are Missing From the Puzzle? 
  • Dynamic right ventricular dimension. Relation to chamber volume during the cardiac cycle. 
  • Dysglycemia and incident heart failure among blacks: The jackson heart study. 
  • Early Adoption of Sacubitril/Valsartan for Patients With Heart Failure With Reduced Ejection Fraction: Insights From Get With the Guidelines-Heart Failure (GWTG-HF). 
  • Early Identification of Patients at Risk for Incident Heart Failure With Preserved Ejection Fraction: Novel Approach to Echocardiographic Trends. 
  • Early Impedance-Guided Intervention Improves Long-Term Outcome in Patients With Heart Failure. 
  • Early and late changes in left ventricular systolic performance after percutaneous aortic balloon valvuloplasty. 
  • Early breast cancer therapy and cardiovascular injury. 
  • Early cardiac dysfunction in children and young adults with perinatally acquired HIV. 
  • Early cardiovascular function and associated hemodynamics in adults with isolated moderate-severe traumatic brain injury: A pilot study. 
  • Early echocardiographic deformation analysis for the prediction of sudden cardiac death and life-threatening arrhythmias after myocardial infarction. 
  • Early effects of right ventricular volume overload on ventricular performance and beta-adrenergic signaling. 
  • Early impact of guideline publication on angiotensin-receptor neprilysin inhibitor use among patients hospitalized for heart failure. 
  • Early regression of severe left ventricular hypertrophy after transcatheter aortic valve replacement is associated with decreased hospitalizations. 
  • Echocardiographic Algorithm for Post-Myocardial Infarction LV Thrombus: A Gatekeeper for Thrombus Evaluation by Delayed Enhancement CMR. 
  • Echocardiographic Assessment of Right Ventricular Function and Response to Therapy in Pulmonary Arterial Hypertension. 
  • Echocardiographic Features Beyond Ejection Fraction and Associated Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction. 
  • Echocardiographic Findings Predict In-Hospital and 1-Year Mortality in Left-Sided Native Valve Staphylococcus aureus Endocarditis: Analysis From the International Collaboration on Endocarditis-Prospective Echo Cohort Study. 
  • Echocardiographic agreement in the diagnostic evaluation for infective endocarditis. 
  • Echocardiography Core Laboratory Reproducibility of Cardiac Safety Assessments in Cardio-Oncology. 
  • Echocardiography-derived tricuspid regurgitant jet velocity is an important marker for the progression of sickle-cell disease. 
  • Economic Evaluation of Catheter Ablation of Atrial Fibrillation in Patients with Heart Failure With Reduced Ejection Fraction. 
  • Effect of Atrial Fibrillation on Mortality, Stroke Risk, and Quality-of-Life Scores in Patients With Heart Failure (from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation [ORBIT-AF]). 
  • Effect of Baseline Left Ventricular Ejection Fraction on 2-Year Outcomes After Transcatheter Aortic Valve Replacement: Analysis of the PARTNER 2 Trials. 
  • Effect of Caloric Restriction or Aerobic Exercise Training on Peak Oxygen Consumption and Quality of Life in Obese Older Patients With Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial. 
  • Effect of Ejection Fraction on Clinical Outcomes in Patients Treated With Omecamtiv Mecarbil in GALACTIC-HF. 
  • Effect of Heart Failure With Preserved Ejection Fraction on Perioperative Outcomes in Patients Undergoing Hip Fracture Surgery. 
  • Effect of Inorganic Nitrite vs Placebo on Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction: The INDIE-HFpEF Randomized Clinical Trial. 
  • Effect of Interleukin-1 Blockade on Left Ventricular Systolic Performance and Work: A Post Hoc Pooled Analysis of 2 Clinical Trials. 
  • Effect of Natriuretic Peptide-Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. 
  • Effect of Novel Programming on Inappropriate Implantable Cardioverter-Defibrillator Therapy in Patients With Very Low Ejection Fraction (from A MADIT-RIT). 
  • Effect of Omecamtiv Mecarbil on Exercise Capacity in Chronic Heart Failure With Reduced Ejection Fraction: The METEORIC-HF Randomized Clinical Trial. 
  • Effect of Oral Iron Repletion on Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction and Iron Deficiency: The IRONOUT HF Randomized Clinical Trial. 
  • Effect of Spironolactone on Exercise Tolerance and Arterial Function in Older Adults with Heart Failure with Preserved Ejection Fraction. 
  • Effect of Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. 
  • Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The VITALITY-HFpEF Randomized Clinical Trial. 
  • Effect of a Hospital and Postdischarge Quality Improvement Intervention on Clinical Outcomes and Quality of Care for Patients With Heart Failure With Reduced Ejection Fraction: The CONNECT-HF Randomized Clinical Trial. 
  • Effect of acutely increased right ventricular afterload on work output from the left ventricle in conscious dogs. Systolic ventricular interaction. 
  • Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial. 
  • Effect of beta-blocking therapy on outcome in the Multicenter UnSustained Tachycardia Trial (MUSTT). 
  • Effect of cardiac cycle on ultrasound assessment of endothelial function. 
  • Effect of exercise training on ventricular function, dyssynchrony, resting myocardial perfusion, and clinical outcomes in patients with heart failure: a nuclear ancillary study of Heart Failure and A Controlled Trial Investigating Outcomes of Exercise TraiNing (HF-ACTION); design and rationale. 
  • Effect of increased body mass index on accuracy of two-dimensional echocardiography for measurement of left ventricular volume, ejection fraction, and mass. 
  • Effect of levosimendan on survival and adverse events after cardiac surgery: a meta-analysis. 
  • Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. 
  • Effect of rate-dependent left bundle branch block on global and regional left ventricular function. 
  • Effect of verapamil on left ventricular function at rest and during exercise in normal men. 
  • Effect on Mortality of Higher Versus Lower β-Blocker (Metoprolol Succinate or Carvedilol) Dose in Patients With Heart Failure. 
  • Effectiveness of Cardiac Resynchronization Therapy by QRS Morphology in the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT). 
  • Effects of Dapagliflozin According to the Heart Failure Collaboratory Medical Therapy Score: Insights From DAPA-HF. 
  • Effects of Elamipretide on Left Ventricular Function in Patients With Heart Failure With Reduced Ejection Fraction: The PROGRESS-HF Phase 2 Trial. 
  • Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE Trial. 
  • Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. 
  • Effects of Liraglutide on Worsening Renal Function Among Patients With Heart Failure With Reduced Ejection Fraction: Insights From the FIGHT Trial. 
  • Effects of Omecamtiv Mecarbil on Symptoms and Health-Related Quality of Life in Patients With Chronic Heart Failure: Results From the COSMIC-HF Study. 
  • Effects of Sacubitril/Valsartan on Serum Lipids in Heart Failure With Preserved Ejection Fraction. 
  • Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients: The Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF) Study. 
  • Effects of a Novel Nitroxyl Donor in Acute Heart Failure: The STAND-UP AHF Study. 
  • Effects of anti-CD18 monoclonal antibody, R15.7, on the cardiopulmonary manifestations of group B streptococcal sepsis in piglets. 
  • Effects of beta-blockers on implantable cardioverter defibrillator therapy and survival in the patients with ischemic cardiomyopathy (from the Multicenter Automatic Defibrillator Implantation Trial-II). 
  • Effects of body surface area-indexed calculations in the morbidly obese: a mathematical analysis. 
  • Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. 
  • Effects of cardiac glycosides on myocardial function and energetics in conscious dogs. 
  • Effects of danicamtiv, a novel cardiac myosin activator, in heart failure with reduced ejection fraction: experimental data and clinical results from a phase 2a trial. 
  • Effects of exercise and weight loss on mental stress-induced cardiovascular responses in individuals with high blood pressure. 
  • Effects of hybrid comprehensive telerehabilitation on cardiopulmonary capacity in heart failure patients depending on diabetes mellitus: subanalysis of the TELEREH-HF randomized clinical trial. 
  • Effects of omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressure: the GALACTIC-HF trial. 
  • Effects of physical conditioning on left ventricular ejection fraction in patients with coronary artery disease. 
  • Effects of reduced left ventricular mass on chamber architecture, load, and function: a study of anorexia nervosa. 
  • Effects of standard mitral valve replacement on left ventricular function. 
  • Effects of steroids and angiotensin converting enzyme inhibition on circumferential strain in boys with Duchenne muscular dystrophy: a cross-sectional and longitudinal study utilizing cardiovascular magnetic resonance. 
  • Effects of the Novel Long-Acting GLP-1 Agonist, Albiglutide, on Cardiac Function, Cardiac Metabolism, and Exercise Capacity in Patients With Chronic Heart Failure and Reduced Ejection Fraction. 
  • Effects of the adenosine A1 receptor antagonist rolofylline on renal function in patients with acute heart failure and renal dysfunction: results from PROTECT (Placebo-Controlled Randomized Study of the Selective Adenosine A1 Receptor Antagonist Rolofylline for Patients Hospitalized with Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function). 
  • Effects of the chymase inhibitor fulacimstat on adverse cardiac remodeling after acute myocardial infarction-Results of the Chymase Inhibitor in Adverse Remodeling after Myocardial Infarction (CHIARA MIA) 2 trial. 
  • Effects of triiodothyronine and vasopressin on cardiac function and myocardial blood flow after brain death. 
  • Effects of valve replacement on ventricular mechanics in mitral regurgitation and aortic stenosis. 
  • Effects of verapamil on postextrasystolic potentiation. 
  • Effects of vericiguat in heart failure with reduced ejection fraction: do not forget sST2. Reply. 
  • Efficacy and Safety of Dapagliflozin According to Frailty in Patients With Heart Failure: A Prespecified Analysis of the DELIVER Trial. 
  • Efficacy and Safety of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction According to Age: The DELIVER Trial. 
  • Efficacy and Safety of Sacubitril/Valsartan by Dose Level Achieved in the PIONEER-HF Trial. 
  • Efficacy and Safety of Spironolactone in Acute Heart Failure: The ATHENA-HF Randomized Clinical Trial. 
  • Efficacy and safety of angiotensin receptor blockade are not modified by aspirin in patients with chronic heart failure: a cohort study from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity (CHARM) programme. 
  • Efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status (DELIVER): a subgroup analysis from an international, multicentre, double-blind, randomised, placebo-controlled trial. 
  • Efficacy and safety of vericiguat in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan: insights from the VICTORIA trial. 
  • Efficacy of Intravenous Furosemide Versus a Novel, pH-Neutral Furosemide Formulation Administered Subcutaneously in Outpatients With Worsening Heart Failure. 
  • Efficacy of omecamtiv mecarbil in heart failure with reduced ejection fraction according to N-terminal pro-B-type natriuretic peptide level: insights from the GALACTIC-HF trial. 
  • Eight-year mortality in the Emory Angioplasty versus Surgery Trial (EAST). 
  • Ejection Fraction, Biomarkers, and Outcomes and Impact of Vericiguat on Outcomes Across EF in VICTORIA. 
  • Ejection fraction assessment and survival: an analysis of the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). 
  • Ejection fraction in left bundle branch block is disproportionately reduced in relation to amount of myocardial scar. 
  • Ejection fraction response to exercise in patients with chest pain and normal coronary arteriograms. 
  • Ejection fraction response to exercise in patients with chest pain, coronary artery disease and normal resting ventricular function. 
  • Ejection load changes in aortic stenosis. Observations made after balloon aortic valvuloplasty. 
  • Electrophysiologic and clinical effects of angiotensin-converting enzyme inhibitors in patients with prior myocardial infarction, nonsustained ventricular tachycardia, and depressed left ventricular function. MUSTT Investigators. Multicenter UnSustained Tachycardia Trial. 
  • Eligibility for sacubitril/valsartan in heart failure across the ejection fraction spectrum: real-world data from the Swedish Heart Failure Registry. 
  • Empagliflozin for Heart Failure With Preserved Left Ventricular Ejection Fraction With and Without Diabetes. 
  • Empagliflozin in patients post myocardial infarction rationale and design of the EMPACT-MI trial. 
  • Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial. 
  • Enalapril in infants with single ventricle: results of a multicenter randomized trial. 
  • End-systolic volume index at 90 to 180 minutes into reperfusion therapy for acute myocardial infarction is a strong predictor of early and late mortality. The Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO)-I Angiographic Investigators. 
  • Endomyocardial Biopsy Characterization of Heart Failure With Preserved Ejection Fraction and Prevalence of Cardiac Amyloidosis. 
  • Endovascular ablation of the right greater splanchnic nerve in heart failure with preserved ejection fraction: early results of the REBALANCE-HF trial roll-in cohort. 
  • Enhancing ejection fraction measurement through 4D respiratory motion compensation in cardiac PET imaging. 
  • Enrollment of Older Patients, Women, and Racial and Ethnic Minorities in Contemporary Heart Failure Clinical Trials: A Systematic Review. 
  • Estimated Long-Term Benefit of Dapagliflozin in Patients With Heart Failure. 
  • Estimation of left ventricular volume and ejection fraction by two-dimensional transoesophageal echocardiography: comparison of short axis imaging and simultaneous radionuclide angiography. 
  • Estimation of the ratio of pulmonary to systemic pressures by pulsed-wave Doppler echocardiography for assessment of pulmonary arterial pressures. 
  • Estimation of wall stress and left ventricular mass by noninvasive techniques and clinical implications. 
  • Evaluating Out-of-Hospital 30-Day Mortality After Transfemoral Transcatheter Aortic Valve Replacement: An STS/ACC TVT Analysis. 
  • Evaluating cardiac physiology through echocardiography in bottlenose dolphins: using stroke volume and cardiac output to estimate systolic left ventricular function during rest and following exercise. 
  • Evaluating the Application of Chronic Heart Failure Therapies and Developing Treatments in Individuals With Recent Myocardial Infarction: A Review. 
  • Evaluation of Flow After Transcatheter Aortic Valve Replacement in Patients With Low-Flow Aortic Stenosis: A Secondary Analysis of the PARTNER Randomized Clinical Trial. 
  • Evaluation of Right Ventricular Myocardial Mechanics Using Velocity Vector Imaging of Cardiac MRI Cine Images in Transposition of the Great Arteries Following Atrial and Arterial Switch Operations. 
  • Evaluation of beta-adrenergic influences on cardiovascular and metabolic adjustments to physical and psychological stress. 
  • Evaluation of right and left ventricular diastolic filling. 
  • Evaluation of the Incremental Prognostic Utility of Increasingly Complex Testing in Chronic Heart Failure. 
  • Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial. 
  • Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial. 
  • Evidence Builds for Catheter Ablation for Atrial Fibrillation and Heart Failure. 
  • Evidence-Based Process Performance Measures and Clinical Outcomes in Patients With Incident Heart Failure With Reduced Ejection Fraction: A Danish Nationwide Cohort Study. 
  • Evolution of Left Ventricular Assist Device Therapy for Advanced Heart Failure: A Review. 
  • Evolution of a Geriatric Syndrome: Pathophysiology and Treatment of Heart Failure with Preserved Ejection Fraction. 
  • Evolving Landscape of Clinical Trials in Heart Failure: Patient Populations, Endpoint Selection, and Regions of Enrollment. 
  • Exercise echocardiographic comparison of pulmonary autograft and aortic homograft replacements for aortic valve disease in adults. 
  • Exercise responses before and after physical conditioning in patients with severely depressed left ventricular function. 
  • Exercise training for prevention and treatment of older adults with heart failure with preserved ejection fraction. 
  • Exercise training of patients with ventricular dysfunction and heart failure. 
  • Expanded algorithm for managing patients with acute decompensated heart failure. 
  • Experimental mitral regurgitation. Physiological effects of correction on left ventricular dynamics. 
  • Extra-cardiac targets in the management of cardiometabolic disease: Device-based therapies. 
  • Extracardiac Abnormalities of Preload Reserve: Mechanisms Underlying Exercise Limitation in Heart Failure with Preserved Ejection Fraction, Autonomic Dysfunction, and Liver Disease. 
  • FGF21-FGFR4 signaling in cardiac myocytes promotes concentric cardiac hypertrophy in mouse models of diabetes. 
  • FGF23 modifies the relationship between vitamin D and cardiac remodeling. 
  • Factors Associated With and Prognostic Implications of Cardiac Troponin Elevation in Decompensated Heart Failure With Preserved Ejection Fraction: Findings From the American Heart Association Get With The Guidelines-Heart Failure Program. 
  • Factors affecting ventricular volumes determined by a count-based equilibrium method. 
  • Factors and outcomes associated with improved left ventricular systolic function in patients with cardiomyopathy. 
  • Factors associated with improvement in ejection fraction in clinical practice among patients with heart failure: findings from IMPROVE HF. 
  • Factors associated with non-use and sub-target dosing of medical therapy for heart failure with reduced ejection fraction. 
  • Factors associated with ventricular inducibility in the MADIT-II study population. 
  • Failure of balloon aortic valvuloplasty to result in sustained clinical improvement in patients with depressed left ventricular function. 
  • Failure of normalized ventricular filling rates to predict true filling rates. 
  • Feasibility and variability of three dimensional echocardiography in arrhythmogenic right ventricular dysplasia/cardiomyopathy. 
  • Feature-Tracking Global Longitudinal Strain Predicts Death in a Multicenter Population of Patients With Ischemic and Nonischemic Dilated Cardiomyopathy Incremental to Ejection Fraction and Late Gadolinium Enhancement. 
  • Feature-Tracking Global Longitudinal Strain Predicts Mortality in Patients With Preserved Ejection Fraction: A Multicenter Study. 
  • Features Associated With Discordance Between Pulmonary Arterial Wedge Pressure and Left Ventricular End Diastolic Pressure in Clinical Practice: Implications for Pulmonary Hypertension Classification. 
  • Fibroblast Growth Factor 23 and Exercise Capacity in Heart Failure with Preserved Ejection Fraction. 
  • Finding the road to recovery: therapeutic and clinical trial implications of dysfunctional viable myocardium in heart failure with reduced ejection fraction. 
  • Firibastat Versus Ramipril After Acute Mechanical Reperfusion of Anterior Myocardial Infarction: A Phase 2 Study. 
  • Fluid dynamic aspects of ejection in hypertrophic cardiomyopathy. 
  • Fluid dynamics of aortic stenosis: mechanisms for the presence of subvalvular pressure gradients. 
  • Fluid dynamics of aortic stenosis: subvalvular gradients without subvalvular obstruction. 
  • Frailty Status Modifies the Efficacy of Exercise Training Among Patients With Chronic Heart Failure and Reduced Ejection Fraction: An Analysis From the HF-ACTION Trial. 
  • Frailty, Guideline-Directed Medical Therapy, and Outcomes in HFrEF: From the GUIDE-IT Trial. 
  • Frequency of transient reductions in left ventricular ejection fraction at rest in coronary artery disease. 
  • Frequency, patient characteristics, and outcomes of mild-to-moderate heart failure complicating ST-segment elevation acute myocardial infarction: lessons from 4 international fibrinolytic therapy trials. 
  • Frequent Activation Delay-Induced Mechanical Dyssynchrony and Dysfunction in the Systemic Right Ventricle. 
  • From Theory to Practice: The Use of Real-World Data to Evaluate New Heart Failure Therapies. 
  • Functional abnormalities in isolated left bundle branch block. The effect of interventricular asynchrony. 
  • Functional state following the Fontan procedure. 
  • Future research prioritization in cardiac resynchronization therapy. 
  • GLP-1 agonist therapy for advanced heart failure with reduced ejection fraction: design and rationale for the functional impact of GLP-1 for heart failure treatment study. 
  • Gadolinium cardiovascular magnetic resonance predicts reversible myocardial dysfunction and remodeling in patients with heart failure undergoing beta-blocker therapy. 
  • Galectin-3 Associated with Severe Forms and Long-term Mortality in Patients with Chagas Disease. 
  • Galectin-3 and mineralocorticoid receptor antagonist use in patients with chronic heart failure due to left ventricular systolic dysfunction. 
  • Galectin-3 in heart failure with preserved ejection fraction. A RELAX trial substudy (Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure). 
  • Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. 
  • Gender does not affect postdischarge outcomes in patients hospitalized for worsening heart failure with reduced ejection fraction (from the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan [EVEREST] Trial). 
  • Generalizability of the CASTLE-AF trial: Catheter ablation for patients with atrial fibrillation and heart failure in routine practice. 
  • Get With The Guidelines program participation, process of care, and outcome for Medicare patients hospitalized with heart failure. 
  • Global Longitudinal Strain and Immune Status in Patients Living With Human Immunodeficiency Virus. 
  • Glycemic status, non-traditional risk and left ventricular structure and function in the Jackson Heart Study. 
  • Goal-Directed Fluid Therapy Using Stroke Volume Variation for Resuscitation after Low Central Venous Pressure-Assisted Liver Resection: A Randomized Clinical Trial. 
  • Goal-directed fluid management with trans-oesophageal Doppler. 
  • Growth differentiation factor-15, treatment with liraglutide, and clinical outcomes among patients with heart failure. 
  • Guideline-Directed Medical Therapy and Survival Following Hospitalization in Patients with Heart Failure. 
  • HFpEF: From Early Observations to Worldwide Awareness. 
  • Haemoconcentration, renal function, and post-discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. 
  • Haemodynamic effects of the nitroxyl donor cimlanod (BMS-986231) in chronic heart failure: a randomized trial. 
  • Haemodynamic effects, safety, and pharmacokinetics of human stresscopin in heart failure with reduced ejection fraction. 
  • Health Status Variation Across Practices in Outpatients With Heart Failure: Insights From the CHAMP-HF (Change the Management of Patients With Heart Failure) Registry. 
  • Health System-Level Performance in Prescribing Guideline-Directed Medical Therapy for Patients With Heart Failure With Reduced Ejection Fraction: Results From the CONNECT-HF Trial. 
  • Health-related quality of life impacts upon 5-year survival after coronary artery bypass surgery. 
  • Healthy Aging and Cardiovascular Function: Invasive Hemodynamics During Rest and Exercise in 104 Healthy Volunteers. 
  • Heart Failure Across the Range of Mildly Reduced and Preserved Ejection Fraction in the United States. 
  • Heart Failure Drug Therapy: New Treatments, New Guidelines. 
  • Heart Failure Duration and Mechanistic Efficacy of Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction. 
  • Heart Failure With Preserved Ejection Fraction Expert Panel Report: Current Controversies and Implications for Clinical Trials. 
  • Heart Failure With Preserved Ejection Fraction and Diabetes: JACC State-of-the-Art Review. 
  • Heart Failure With Preserved, Borderline, and Reduced Ejection Fraction: 5-Year Outcomes. 
  • Heart Failure With Reduced Ejection Fraction in Human Immunodeficiency Virus Infection: The More Things Stay the Same. 
  • Heart Failure with Preserved Ejection Fraction in Older Adults. 
  • Heart failure drug treatment. 
  • Heart failure during cardiac pacing. 
  • Heart failure in elderly patients: distinctive features and unresolved issues. 
  • Heart failure medications prescribed at discharge for patients with left ventricular assist devices. 
  • Heart failure preserved ejection fraction (HFpEF): an integrated and strategic review. 
  • Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. 
  • Heart failure with mid-range ejection fraction: pro and cons of the new classification of Heart Failure by European Society of Cardiology guidelines. 
  • Heart failure with preserved ejection fraction in the elderly: scope of the problem. 
  • Heart failure with preserved ejection fraction: New approaches to diagnosis and management. 
  • Heart failure with preserved ejection fraction: a heterogenous disorder with multifactorial pathophysiology. 
  • Heart failure with preserved ejection fraction: comparison of patients with and without angina pectoris (from the Duke Databank for Cardiovascular Disease). 
  • Heart failure with preserved left ventricular systolic function among patients with non-ST-segment elevation acute coronary syndromes. 
  • Heart rate variability assessment early after acute myocardial infarction. Pathophysiological and prognostic correlates. GUSTO ECG Substudy Investigators. Global Utilization of Streptokinase and TPA for Occluded Arteries. 
  • Heart reduction surgery: an analysis of the impact on cardiac function. 
  • Heart Failure Hospitalization and Guideline-Directed Prescribing Patterns Among Heart Failure With Reduced Ejection Fraction Patients. 
  • Heart Failure Management Under Pressure. 
  • Hemodynamic and sympathetic nervous system responses to stress during the menstrual cycle. 
  • Hemodynamic consequences of right ventricular isolation: the contribution of the right ventricular free wall to cardiac performance. 
  • Hemodynamic correlates for timing intervals, ejection rate and filling rate derived from the radionuclide angiographic volume curve. 
  • Hemodynamics of the Mueller maneuver in man: right and left heart micromanometry and Doppler echocardiography. 
  • Hemoglobin and Clinical Outcomes in the Vericiguat Global Study in Patients With Heart Failure and Reduced Ejection Fraction (VICTORIA). 
  • Hepatocyte Growth Factor and Incident Heart Failure Subtypes: The Multi-Ethnic Study of Atherosclerosis (MESA). 
  • Heterogeneity of health status treatment response with sacubitril/valsartan: insights from the CHAMP-HF registry. 
  • Heterogeneous Outcomes of Heart Failure with Better Ejection Fraction. 
  • High-Density Lipoprotein Particle Subfractions in Heart Failure With Preserved or Reduced Ejection Fraction. 
  • High-Sensitivity Troponin I in Hospitalized and Ambulatory Patients With Heart Failure With Preserved Ejection Fraction: Insights From the Heart Failure Clinical Research Network. 
  • High-dose doxorubicin, etoposide, and cyclophosphamide with stem cell reinfusion in patients with metastatic or high-risk primary breast cancer. City of Hope Bone Marrow Oncology Team. 
  • High-risk percutaneous coronary intervention is associated with reverse left ventricular remodeling and improved outcomes in patients with coronary artery disease and reduced ejection fraction. 
  • High-sensitivity C-reactive protein and parameters of left ventricular dysfunction. 
  • Highest Obesity Category Associated With Largest Decrease in N-Terminal Pro-B-Type Natriuretic Peptide in Patients Hospitalized With Heart Failure With Preserved Ejection Fraction. 
  • Highlights of Heart Rhythm 2005, the Annual Scientific Sessions of the Heart Rhythm Society, May 4-7, 2005, New Orleans, Louisiana. 
  • Histologic and biochemical correlates of left ventricular chamber dynamics in man. 
  • History of Atrial Fibrillation and Trajectory of Decongestion in Acute Heart Failure. 
  • Hospitalizations and Prognosis in Elderly Patients With Heart Failure and Preserved Ejection Fraction: Time to Treat the Whole Patient. 
  • Hydroxychloroquine: a treatable cause of cardiomyopathy. 
  • Hypertension as a Road to Treatment of Heart Failure with Preserved Ejection Fraction. 
  • INDIE-HFpEF (Inorganic Nitrite Delivery to Improve Exercise Capacity in Heart Failure With Preserved Ejection Fraction): Rationale and Design. 
  • INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support) Profiling Identifies Ambulatory Patients at High Risk on Medical Therapy After Hospitalizations for Heart Failure. 
  • Ideal methodology to assess systemic blood pressure in patients with continuous-flow left ventricular assist devices. 
  • Identifying patients at increased risk for poor outcomes from heart failure with reduced ejection fraction: the PROMPT-HF risk model. 
  • Identifying responders to oral iron supplementation in heart failure with a reduced ejection fraction: a post-hoc analysis of the IRONOUT-HF trial. 
  • Impact of Age on Comorbidities and Outcomes in Heart Failure With Reduced Ejection Fraction. 
  • Impact of Current Versus Previous Cardiac Resynchronization Therapy Guidelines on the Proportion of Patients With Heart Failure Eligible for Therapy. 
  • Impact of Ejection Fraction and Aortic Valve Gradient on Outcomes of Transcatheter Aortic Valve Replacement. 
  • Impact of Physiologic Pacing Versus Right Ventricular Pacing Among Patients With Left Ventricular Ejection Fraction Greater Than 35%: A Systematic Review for the 2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. 
  • Impact of atrial fibrillation on exercise capacity in heart failure with preserved ejection fraction: a RELAX trial ancillary study. 
  • Impact of cardiovascular magnetic resonance on management and clinical decision-making in heart failure patients. 
  • Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. 
  • Impact of early, late, and no ST-segment resolution measured by continuous ST Holter monitoring on left ventricular ejection fraction and infarct size as determined by cardiovascular magnetic resonance imaging. 
  • Impact of initial norwood shunt type on right ventricular deformation: the single ventricle reconstruction trial. 
  • Impact of intravenous beta-blockade before primary angioplasty on survival in patients undergoing mechanical reperfusion therapy for acute myocardial infarction. 
  • Impact of left ventricular ejection fraction on clinical outcomes over five years after infarct-related coronary artery recanalization (from the Occluded Artery Trial [OAT]). 
  • Impact of mitral regurgitation in patients with acute heart failure: insights from the RELAX-AHF-2 trial. 
  • Impact of patient-specific factors, irradiated left ventricular volume, and treatment set-up errors on the development of myocardial perfusion defects after radiation therapy for left-sided breast cancer. 
  • Impact of physiologic pacing versus right ventricular pacing among patients with left ventricular ejection fraction greater than 35%: A systematic review for the 2018 ACC/AHA/HRS guideline on the evaluation and management of patients with bradycardia and cardiac conduction delay: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. 
  • Impaired chronotropic and vasodilator reserves limit exercise capacity in patients with heart failure and a preserved ejection fraction. 
  • Impaired left ventricular global longitudinal strain in patients with heart failure with preserved ejection fraction: insights from the RELAX trial. 
  • Impaired resting myocardial annular velocities are independently associated with mental stress-induced ischemia in coronary heart disease. 
  • Implantable Cardioverter Defibrillator Utilization and Mortality Among Patients ≥65 Years of Age With a Low Ejection Fraction After Coronary Revascularization. 
  • Implantable Cardioverter-Defibrillator Use Among Medicare Patients With Low Ejection Fraction After Acute Myocardial Infarction. 
  • Implantable cardioverter-defibrillators in heart failure patients with reduced ejection fraction and diabetes. 
  • Implication of right ventricular dysfunction on long-term outcome in patients with ischemic cardiomyopathy undergoing coronary artery bypass grafting with or without surgical ventricular reconstruction. 
  • Implications of Altered Ketone Metabolism and Therapeutic Ketosis in Heart Failure. 
  • Implications of elevated cardiac troponin T in ambulatory patients with heart failure: a prospective analysis. 
  • Implications of peripheral oedema in heart failure with preserved ejection fraction: a heart failure network analysis. 
  • Importance of clinical measures of ischemia in the prognosis of patients with documented coronary artery disease. 
  • Importance of early and complete reperfusion to achieve myocardial salvage after thrombolysis in acute myocardial infarction. 
  • Importance of echocardiography in patients with severe nonischemic heart failure: the second Prospective Randomized Amlodipine Survival Evaluation (PRAISE-2) echocardiographic study. 
  • Importance of imaging method over imaging modality in noninvasive determination of left ventricular volumes and ejection fraction: assessment by two- and three-dimensional echocardiography and magnetic resonance imaging. 
  • Improved cardiac anthropomorphic phantom. 
  • Improved near-term coronary artery disease risk classification with gated stress myocardial perfusion SPECT. 
  • Improved tolerance of the pediatric myocardium to brain death. 
  • Improvement in Left Ventricular Ejection Fraction in Outpatients With Heart Failure With Reduced Ejection Fraction: Data From CHAMP-HF. 
  • Improvement in left ventricular function following higher-risk percutaneous coronary intervention in patients with ischemic cardiomyopathy. 
  • Improvement in the function of hibernating myocardium in a patient with heart failure due to coronary artery disease receiving high-dose simvastatin. 
  • Improvement of Health Status Following Initiation of Sacubitril/Valsartan in Heart Failure and Reduced Ejection Fraction. 
  • In HF with LVEF ≤ 42.5%, sacubitril-valsartan vs RAS inhibitors reduced a composite of CV death or HF hospitalization. 
  • In HFpEF, the benefit of empagliflozin on a composite of CV death or HF hospitalization at 26 mo did not vary by diabetes status. 
  • In vitro analysis of jets by Doppler colour flow imaging: the importance of time to maximum jet area. 
  • In vivo assessment of left ventricular remodelling after myocardial infarction by digital video contrast angiography in the rat. 
  • In-Hospital Initiation of Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure With Reduced Ejection Fraction. 
  • In-Hospital Therapy for Heart Failure With Reduced Ejection Fraction in the United States. 
  • In-Hospital Virtual Peer-to-Peer Consultation to Increase Guideline-Directed Medical Therapy for Heart Failure: A Pilot Randomized Trial. 
  • In-Hospital and Three-Year Outcomes of Heart Failure Patients in South India: The Trivandrum Heart Failure Registry. 
  • In-hospital initiation of quadruple medical therapy for heart failure: making the post-discharge vulnerable phase far less vulnerable. 
  • Inappropriate implantable cardioverter-defibrillator shocks in MADIT II: frequency, mechanisms, predictors, and survival impact. 
  • Incidence and Outcomes of Acute Heart Failure With Preserved Versus Reduced Ejection Fraction in SPRINT. 
  • Incidence, Prognosis and Predictors of Major Vascular Complications and Percutaneous Closure Device Failure Following Contemporary Percutaneous Transfemoral Transcatheter Aortic Valve Replacement. 
  • Increased ketone body oxidation provides additional energy for the failing heart without improving cardiac efficiency. 
  • Increased levels of uric acid predict haemodynamic compromise in patients with heart failure independently of B-type natriuretic peptide levels. 
  • Increased lipofuscin on endomyocardial biopsy predicts greater cardiac improvement in adolescents and young adults. 
  • Incremental prognostic value of RNA ejection fraction measurements during pharmacologic stress testing: a comparison with clinical and perfusion variables. 
  • Index of contractile asymmetry improves patient selection for CRT: a proof-of-concept study. 
  • Individual-Specific, Beat-to-beat Trending of Significant Human Blood Loss: The Compensatory Reserve. 
  • Inducible myocardial ischemia and outcomes in patients with coronary artery disease and left ventricular dysfunction. 
  • Infarct morphology identifies patients with substrate for sustained ventricular tachycardia. 
  • Infarct size and left ventricular function in the PRoximal Embolic Protection in Acute myocardial infarction and Resolution of ST-segment Elevation (PREPARE) trial: ancillary cardiovascular magnetic resonance study. 
  • Infarct size, left ventricular function, and prognosis in women compared to men after primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: results from an individual patient-level pooled analysis of 10 randomized trials. 
  • Influence of Cardiac Remodeling on Clinical Outcomes in Patients With Aortic Regurgitation. 
  • Influence of NT-proBNP on Efficacy of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction. 
  • Influence of QRS infarct score and QRS duration prior to transcatheter aortic valve replacement on follow-up left ventricular end systolic volume in patients with new persistent left bundle branch block. 
  • Influence of atrial fibrillation on efficacy and safety of omecamtiv mecarbil in heart failure: the GALACTIC-HF trial. 
  • Influence of baseline left ventricular function on the clinical outcome of surgical ventricular reconstruction in patients with ischaemic cardiomyopathy. 
  • Influence of documented history of coronary artery disease on outcomes in patients admitted for worsening heart failure with reduced ejection fraction in the EVEREST trial. 
  • Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. 
  • Influence of heart failure symptoms and ejection fraction on short- and long-term outcomes for older patients with non-ST-segment elevation myocardial infarction. 
  • Influence of hospitalization for cardiovascular versus noncardiovascular reasons on subsequent mortality in patients with chronic heart failure across the spectrum of ejection fraction. 
  • Influence of lung volume on the interaction between cardiac output and cerebrovascular regulation during extreme apnoea. 
  • Influence of mitral regurgitation repair on survival in the surgical treatment for ischemic heart failure trial. 
  • Influence of previous heart failure hospitalization on cardiovascular events in patients with reduced and preserved ejection fraction. 
  • Influence of renal function on the use of guideline-recommended therapies for patients with heart failure. 
  • Influence of the timing of cardiac catheterization and the amount of contrast media on acute renal failure after cardiac surgery. 
  • Initial safety analysis of a randomized phase II trial of nelipepimut-S + GM-CSF and trastuzumab compared to trastuzumab alone to prevent recurrence in breast cancer patients with HER2 low-expressing tumors. 
  • Initiation, Continuation, Switching, and Withdrawal of Heart Failure Medical Therapies During Hospitalization. 
  • Initiation, Continuation, or Withdrawal of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers and Outcomes in Patients Hospitalized With Heart Failure With Reduced Ejection Fraction. 
  • Insights derived from the thrombolysis and angioplasty in myocardial infarction (TAMI) trials. 
  • Insights from the STICH trial: change in left ventricular size after coronary artery bypass grafting with and without surgical ventricular reconstruction. 
  • Insufficient reduction in heart rate during hospitalization despite beta-blocker treatment in acute decompensated heart failure: insights from the ASCEND-HF trial. 
  • Insulin Growth Factor Phenotypes in Heart Failure With Preserved Ejection Fraction, an INSPIRE Registry and CATHGEN Study. 
  • Insulin resistance in heart failure: widening the divide between reduced and preserved ejection fraction? 
  • Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fraction. 
  • Insulin-Like Growth Factor-Binding Protein-7 as a Biomarker of Diastolic Dysfunction and Functional Capacity in Heart Failure With Preserved Ejection Fraction: Results From the RELAX Trial. 
  • Intensity and focus of heart failure disease management after hospital discharge. 
  • Interactions between transvenous nonthoracotomy cardioverter defibrillator systems and permanent transvenous endocardial pacemakers. 
  • Interatrial Stent to Treat Stiff Left Atrium Syndrome. 
  • Intercountry Differences in Guideline-Directed Medical Therapy and Outcomes Among Patients With Heart Failure. 
  • Interleukin-1 Blockade in Recently Decompensated Systolic Heart Failure: Results From REDHART (Recently Decompensated Heart Failure Anakinra Response Trial). 
  • International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. 
  • International variation in characteristics and clinical outcomes of patients with type 2 diabetes and heart failure: Insights from TECOS. 
  • Intersection of atrial fibrillation and heart failure with mildly reduced and preserved ejection fraction in >400 000 participants in the Get With The Guidelines-Heart Failure Registry. 
  • Intra-arterial reserpine for Raynaud's syndrome. Systemic reactions without therapeutic benefit. 
  • Intracardiac transplantation of a mixed population of bone marrow cells improves both regional systolic contractility and diastolic relaxation. 
  • Intracoronary ALLogeneic heart STem cells to Achieve myocardial Regeneration (ALLSTAR): a randomized, placebo-controlled, double-blinded trial. 
  • Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial. 
  • Intramyocardial Injection of Mesenchymal Precursor Cells and Successful Temporary Weaning From Left Ventricular Assist Device Support in Patients With Advanced Heart Failure: A Randomized Clinical Trial. 
  • Investigating gender-based differential item functioning on the Kansas City Cardiomyopathy Questionnaire (KCCQ) using qualitative content analysis. 
  • Invited commentary. 
  • Iodine-123 MIBG imaging before treatment of heart failure with carvedilol to predict improvement of left ventricular function and exercise capacity. 
  • Ischemia-Mediated Dysfunction in Subpapillary Myocardium as a Marker of Functional Mitral Regurgitation. 
  • Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction. 
  • LV twisting and untwisting in HCM: ejection begets filling. Diastolic functional aspects of HCM. 
  • Lack of Association Between Anemia and Intrinsic Left Ventricular Diastolic Function or Cardiac Mechanics in Heart Failure With Preserved Ejection Fraction. 
  • Late gadolinium enhancement magnetic resonance imaging in the diagnosis and prognosis of endomyocardial fibrosis patients. 
  • Lead one ratio in left bundle branch block predicts poor cardiac resynchronization therapy response. 
  • Left Atrial Stiffness Index Independently Predicts Exercise Intolerance and Quality of Life in Older, Obese Patients With Heart Failure With Preserved Ejection Fraction. 
  • Left Atrial Structure and Function in Heart Failure with Preserved Ejection Fraction: A RELAX Substudy. 
  • Left Ventricular Ejection Fraction Monitoring Adherence Rates: Why So Low? 
  • Left Ventricular Global Longitudinal Strain Can Reliably Be Measured from a Single Apical Four-Chamber View in Patients with Heart Failure. 
  • Left Ventricular Long-Axis Function Assessed with Cardiac Cine MR Imaging Is an Independent Predictor of All-Cause Mortality in Patients with Reduced Ejection Fraction: A Multicenter Study. 
  • Left atrial decompression pump for severe heart failure with preserved ejection fraction: theoretical and clinical considerations. 
  • Left atrial function in heart failure with preserved ejection fraction: a systematic review and meta-analysis. 
  • Left bundle branch block in non-ST-segment elevation acute coronary syndromes. Incidence, angiographic characteristics, and clinical outcomes. 
  • Left bundle branch block-induced left ventricular remodeling and its potential for reverse remodeling. 
  • Left bundle-branch block is associated with asimilar dyssynchronous phenotype in heart failure patients with normal and reduced ejection fractions. 
  • Left ventricular diastolic dysfunction and exercise intolerance in obese heart failure with preserved ejection fraction. 
  • Left ventricular ejection fraction after acute coronary occlusion in conscious dogs: relation to the extent and site of myocardial infarction. 
  • Left ventricular ejection fraction test rates for Medicare beneficiaries with heart failure. 
  • Left ventricular endocardial irregularity: evaluation using epicardial echocardiography. 
  • Left ventricular function under stress before and after myocardial revascularization. 
  • Left ventricular global longitudinal strain in patients with heart failure with preserved ejection fraction: outcomes following an acute heart failure hospitalization. 
  • Left ventricular hypertrophy in athletes: morphologic features and clinical correlates. 
  • Left ventricular hypertrophy patterns and incidence of heart failure with preserved versus reduced ejection fraction. 
  • Left ventricular performance improves late after aortic valve replacement in patients with aortic stenosis and reduced ejection fraction. 
  • Left ventricular regional contraction abnormalities by echocardiographic speckle tracking in combined right bundle branch with left anterior fascicular block compared to left bundle branch block. 
  • Left ventricular remodelling and disparate changes in contractility and relaxation during the development of and recovery from experimental heart failure. 
  • Levosimendan in Patients with Left Ventricular Dysfunction Undergoing Cardiac Surgery. 
  • Levosimendan in patients with left ventricular systolic dysfunction undergoing cardiac surgery on cardiopulmonary bypass: Rationale and study design of the Levosimendan in Patients with Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery Requiring Cardiopulmonary Bypass (LEVO-CTS) trial. 
  • Limitations of ejection fraction for prediction of sudden death risk in patients with coronary artery disease: lessons from the MUSTT study. 
  • Linearity of the Frank-Starling relationship in the intact heart: the concept of preload recruitable stroke work. 
  • Liraglutide and weight loss among patients with advanced heart failure and a reduced ejection fraction: insights from the FIGHT trial. 
  • Liver function tests in patients with acute heart failure and associated outcomes: insights from ASCEND-HF. 
  • Load-independent analysis of a pulsatile right ventricular assist device. 
  • Localization of the site of ventricular premature complexes by radionuclide angiographic phase imaging. 
  • Long-Term Cognitive Decline After Newly Diagnosed Heart Failure: Longitudinal Analysis in the CHS (Cardiovascular Health Study). 
  • Long-term Cardiopulmonary Consequences of Treatment-Induced Cardiotoxicity in Survivors of ERBB2-Positive Breast Cancer. 
  • Long-term ambulatory therapy with prazosin versus placebo for chronic heart failure: relation between clinical response and left ventricular function at rest and during exercise. 
  • Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. 
  • Long-term outcome after biologic versus mechanical aortic valve replacement in 841 patients. 
  • Long-term outcomes for heart failure patients with and without diabetes: From the Get With The Guidelines-Heart Failure Registry. 
  • Long-term outcomes of mitral regurgitation by type and severity. 
  • Long-term survival of patients with ischemic cardiomyopathy treated by coronary artery bypass grafting versus medical therapy. 
  • Longitudinal Changes in Cardiac Troponin and Risk of Heart Failure Among Black Adults. 
  • Longitudinal Hemodynamics of Transcatheter and Surgical Aortic Valves in the PARTNER Trial. 
  • Longitudinal Observational Study of Cardiac Outcome Risk Factor Prediction in Children, Adolescents, and Adults with Barth Syndrome. 
  • Longitudinal Strain in Heart Failure With Preserved Ejection Fraction: Is There a Role for Prognostication? 
  • Loop Diuretic Use and Outcomes in Chronic Stable Heart Failure With Preserved Ejection Fraction-Reply. 
  • Loop diuretic adjustments in patients with chronic heart failure: Insights from HF-ACTION. 
  • Low lead one ratio predicts clinical outcomes in left bundle branch block. 
  • Machine Learning Algorithm Predicts Cardiac Resynchronization Therapy Outcomes: Lessons From the COMPANION Trial. 
  • Machine Learning Methods Improve Prognostication, Identify Clinically Distinct Phenotypes, and Detect Heterogeneity in Response to Therapy in a Large Cohort of Heart Failure Patients. 
  • Machine learning to define phenotypes and outcomes of patients hospitalized for heart failure with preserved ejection fraction: Findings from ASCEND-HF. 
  • Magnetic resonance imaging--cardiac ejection fraction measurements. Phantom study comparing four different methods. 
  • Making the case for sacubitril/valsartan in patients with heart failure with a preserved ejection fraction. 
  • Management of Heart Failure With Reduced Ejection Fraction. 
  • Management of Heart Failure with Preserved Ejection Fraction: Current Challenges and Future Directions. 
  • Management of hypertension in heart failure with preserved ejection fraction: is there a blood pressure goal? 
  • Markers of decongestion, dyspnea relief, and clinical outcomes among patients hospitalized with acute heart failure. 
  • Maternal Obesity Affects Cardiac Remodeling and Recovery in Women with Peripartum Cardiomyopathy. 
  • Mavacamten Treatment for Obstructive Hypertrophic Cardiomyopathy: A Clinical Trial. 
  • Measured Versus Estimated Resting Metabolic Rate in Heart Failure With Preserved Ejection Fraction. 
  • Measures of Ventricular-Arterial Coupling and Incident Heart Failure With Preserved Ejection Fraction: A Matched Case-Control Analysis. 
  • Mechanical dyssynchrony evaluated by tissue Doppler cross-correlation analysis is associated with long-term survival in patients after cardiac resynchronization therapy. 
  • Mechanisms and Models in Heart Failure: A Translational Approach. 
  • Mechanisms of current therapeutic strategies for heart failure: more questions than answers? 
  • Mechanisms of functional mitral regurgitation in ischemic cardiomyopathy determined by transesophageal echocardiography (from the Surgical Treatment for Ischemic Heart Failure Trial). 
  • Mechanistic Efficacy of Sacubitril/Valsartan in Ischemic Versus Nonischemic Heart Failure. 
  • Medical Management of Heart Failure With Reduced Ejection Fraction in Patients With Advanced Renal Disease. 
  • Medical Therapy During Hospitalization for Heart Failure With Reduced Ejection Fraction: The VICTORIA Registry. 
  • Medical Therapy for Heart Failure With Reduced Ejection Fraction: The CHAMP-HF Registry. 
  • Medical, psychological and social correlates of work disability among men with coronary artery disease. 
  • Medicare Expenditures by Race/Ethnicity After Hospitalization for Heart Failure With Preserved Ejection Fraction. 
  • Medication Trajectory and Treatment Patterns in Medicare Patients With Heart Failure and Reduced Ejection Fraction. 
  • Medication dosing for heart failure with reduced ejection fraction - opportunities and challenges. 
  • Medication-Attributable Adverse Events in Heart Failure Trials. 
  • Meet Me in the Middle: Lessons From the Cardiorenal Advisory Committee for Sacubitril/Valsartan in HFpEF. 
  • Mental stress-induced left ventricular dysfunction and adverse outcome in ischemic heart disease patients. 
  • Meta-Analysis of Efficacy of Sacubitril/Valsartan in Heart Failure With Preserved Ejection Fraction. 
  • Metaanalysis on effects of cardiac resynchronization therapy in heart failure patients with narrow QRS complex. 
  • Metabolomic Profiling Identifies Novel Circulating Biomarkers of Mitochondrial Dysfunction Differentially Elevated in Heart Failure With Preserved Versus Reduced Ejection Fraction: Evidence for Shared Metabolic Impairments in Clinical Heart Failure. 
  • Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure With Reduced Ejection Fraction: DEFINE-HF. 
  • Methodological guidelines for impedance cardiography. 
  • Mineralocorticoid Receptor Antagonism for the Treatment of AF and HFpEF: Preserving Hope. 
  • Mineralocorticoid receptor antagonist use in hospitalized patients with heart failure, reduced ejection fraction, and diabetes mellitus (from the EVEREST Trial). 
  • Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. 
  • Misleading indexed hemodynamic parameters: the clinical importance of discordant BMI and BSA at extremes of weight. 
  • Missing the True Target in Advanced Heart Failure: It Is Time to Look in the Mirror. 
  • Mitral regurgitation in left ventricular noncompaction cardiomyopathy assessed by cardiac MRI. 
  • Mitral valve replacement for isolated mitral regurgitation: analysis of clinical course and late postoperative left ventricular ejection fraction. 
  • Mitral-valve repair versus replacement for severe ischemic mitral regurgitation. 
  • Molecular and functional mechanisms of right ventricular adaptation in chronic pulmonary hypertension. 
  • Mortality after myocardial infarction: the role of renal function and systolic and diastolic functions of the left ventricle. 
  • Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. 
  • Mortality risk associated with ejection fraction differs across resting nuclear perfusion findings. 
  • Multi-ethnic comparisons of diabetes in heart failure with reduced ejection fraction: insights from the HF-ACTION trial and the ASIAN-HF registry. 
  • Multiple biomarkers at admission are associated with angiographic, electrocardiographic, and imaging cardiovascular mechanistic markers of outcomes in patients undergoing primary percutaneous coronary intervention for acute ST-elevation myocardial infarction. 
  • Multiple cArdiac seNsors for mAnaGEment of Heart Failure (MANAGE-HF) - Phase I Evaluation of the Integration and Safety of the HeartLogic Multisensor Algorithm in Patients With Heart Failure. 
  • Myocardial Damage Detected by Late Gadolinium Enhancement Cardiac Magnetic Resonance Is Uncommon in Peripartum Cardiomyopathy. 
  • Myocardial Energetics in Heart Failure With Preserved Ejection Fraction. 
  • Myocardial Fibrosis Progression in Duchenne and Becker Muscular Dystrophy: A Randomized Clinical Trial. 
  • Myocardial Viability and Long-Term Outcomes in Ischemic Cardiomyopathy. 
  • Myocardial fibrosis detected with Gadolinium Delayed Enhancement in Cardiac Magnetic Resonance Imaging and Ventriculoarterial Coupling alterations in patients with Acute Myocarditis. 
  • Myocardial function in hearts with transgenic overexpression of the G protein-coupled receptor kinase 5. 
  • Myocardial perfusion, function, and dyssynchrony in patients with heart failure: baseline results from the single-photon emission computed tomography imaging ancillary study of the Heart Failure and A Controlled Trial Investigating Outcomes of Exercise TraiNing (HF-ACTION) Trial. 
  • N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes: Vericiguat Heart Failure With Reduced Ejection Fraction Study. 
  • N-terminal pro-brain natriuretic peptide and outcomes in patients undergoing surgical ventricular restoration. 
  • NT-proBNP Goal Achievement Is Associated With Significant Reverse Remodeling and Improved Clinical Outcomes in HFrEF. 
  • National Trends in the Burden of Atrial Fibrillation During Hospital Admissions for Heart Failure. 
  • Natriuretic Peptide Response and Outcomes in Chronic Heart Failure With Reduced Ejection Fraction. 
  • Natriuretic Peptides as Inclusion Criteria in Clinical Trials: A JACC: Heart Failure Position Paper. 
  • Natriuretic peptide-guided heart failure management. 
  • Nebivolol in older adults with heart failure: reduced rates for seniors? 
  • Newer Drugs to Reduce High Blood Pressure and Mitigate Hypertensive Target Organ Damage. 
  • Nitrate's effect on activity tolerance in heart failure with preserved ejection fraction trial: rationale and design. 
  • No benefit from defibrillation threshold testing in the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial). 
  • Nomenclature in heart failure: a call for objective, reproducible, and biologically-driven terminology. 
  • Non-geometric echocardiographic indices of ventricular function in patients with a Fontan circulation. 
  • Nonalcoholic Fatty Liver Disease and Risk of Heart Failure Among Medicare Beneficiaries. 
  • Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction. 
  • Noninvasive assessment of hemodynamics: an emphasis on bioimpedance cardiography. 
  • Noninvasive assessment of intrinsic ventricular load dynamics in dilated cardiomyopathy. 
  • Noninvasive assessment of patients following coronary artery angioplasty. 
  • Noninvasive assessment of pulmonary vascular resistance using Doppler tissue imaging of the tricuspid annulus. 
  • Nonobstructive left ventricular ejection pressure gradients in man. 
  • Nonplatelet thromboxane generation is associated with impaired cardiovascular performance and mortality in heart failure. 
  • Nonsustained ventricular tachycardia in coronary artery disease: relation to inducible sustained ventricular tachycardia. MUSTT Investigators. 
  • Normal skeletal muscle Na(+)-K(+) pump concentration in patients with chronic heart failure. 
  • Novel Biomarkers for the Risk Stratification of Heart Failure with Preserved Ejection Fraction. 
  • Novel Mitochondria-Targeting Peptide in Heart Failure Treatment: A Randomized, Placebo-Controlled Trial of Elamipretide. 
  • Novel approaches to the management of chronic systolic heart failure: future directions and unanswered questions. 
  • Novel methodology for echocardiographic quantification of cardiac shape. 
  • Obese-Inflammatory Phenotypes in Heart Failure With Preserved Ejection Fraction. 
  • Obesity Status and Physical Rehabilitation in Older Patients Hospitalized With Acute HF: Insights From REHAB-HF. 
  • Omecamtiv Mecarbil in Black Patients With Heart Failure and Reduced Ejection Fraction: Insights From GALACTIC-HF. 
  • Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction: Rationale and Design of GALACTIC-HF. 
  • Omecamtiv Mecarbil in Systolic Heart Failure. 
  • Omecamtiv Mecarbil in Systolic Heart Failure. Reply. 
  • Omecamtiv Mecarbil: Decisional Dilemmas and Regulatory Science - Opportunities for Improvement? 
  • Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials. 
  • On mechanisms of improved ejection fraction by early reperfusion in acute myocardial infarction: myocardial salvage or infarct stiffening? 
  • One-year mortality after implantable cardioverter-defibrillator placement within the Veterans Affairs Health System. 
  • Optimal Background Pharmacological Therapy for Heart Failure Patients in Clinical Trials: JACC Review Topic of the Week. 
  • Optimal determination of right ventricular filling dynamics in systemic hypertension. 
  • Optimal medical therapy with or without surgical revascularization and long-term outcomes in ischemic cardiomyopathy. 
  • Optimizing The Management of Obese HFpEF Phenotype: Can We Mind Both The Heart and The Kidney? 
  • Orthostatic effects on echocardiographic measures of ventricular function. 
  • Out-of-pocket payments for part d covered medications by medicare fee-for-service beneficiaries with heart failure with reduced ejection fraction. 
  • Outcome of patients with diabetes mellitus and acute myocardial infarction treated with thrombolytic agents. The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. 
  • Outcomes and worsening renal function in patients hospitalized with heart failure with preserved ejection fraction. 
  • Outcomes by race and etiology of patients with left ventricular systolic dysfunction. 
  • Outcomes in advanced heart failure patients with left ventricular assist devices for destination therapy. 
  • Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population. 
  • Outcomes of Cardiac Resynchronization Therapy with Image-Guided Left Ventricular Lead Placement at the Site of Latest Mechanical Activation: A Systematic Review and Meta-Analysis. 
  • Outcomes of bailout percutaneous ventricular assist device versus prophylactic strategy in patients undergoing nonemergent percutaneous coronary intervention. 
  • Outcomes of implantable cardioverter-defibrillator use in patients with comorbidities: results from a combined analysis of 4 randomized clinical trials. 
  • Outcomes of transcatheter and surgical aortic valve replacement in high-risk patients with aortic stenosis and left ventricular dysfunction: results from the Placement of Aortic Transcatheter Valves (PARTNER) trial (cohort A). 
  • Outcomes research in cardiovascular imaging: report of a workshop sponsored by the National Heart, Lung, and Blood Institute. 
  • PINOT NOIR: pulmonic insufficiency improvement with nitric oxide inhalational response. 
  • Partial adenosine A1 receptor agonism: a potential new therapeutic strategy for heart failure. 
  • Participation in a Heart Failure Clinical Trial: Perspectives and Opportunities From the VICTORIA Trial and VICTORIA Simultaneous Registry. 
  • Pathophysiology and time course of silent myocardial ischaemia during mental stress: clinical, anatomical, and physiological correlates. 
  • Patient Characteristics, Outcomes, and Effects of Dapagliflozin According to the Duration of Heart Failure: A Prespecified Analysis of the DELIVER Trial. 
  • Patient motion compensation during transthoracic 3-D echocardiography. 
  • Patient selection in heart failure with preserved ejection fraction clinical trials. 
  • Patient survival characteristics after routine mitral valve repair for ischemic mitral regurgitation. 
  • Patient-Reported Frailty and Functional Status in Heart Failure With Preserved Ejection Fraction: Insights From VITALITY-HFpEF. 
  • Patient-reported and Clinical Outcomes Among Patients Hospitalized for Heart Failure With Reduced Versus Preserved Ejection Fraction. 
  • Patient-reported outcomes for heart failure with preserved ejection fraction: conducting quality studies on quality of life. 
  • Patients Hospitalized for De Novo Versus Worsening Chronic Heart Failure in the United States. 
  • Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial. 
  • Percutaneous coronary intervention in patients with stable coronary artery disease and left ventricular systolic dysfunction: insights from the VA CART program. 
  • Percutaneous left ventricular assist device for high-risk percutaneous coronary interventions: Real-world versus clinical trial experience. 
  • Percutaneous mitral valve repair in the initial EVEREST cohort: evidence of reverse left ventricular remodeling. 
  • Percutaneous transluminal coronary angioplasty as palliation for patients considered poor surgical candidates. 
  • Perioperative Fluid Therapy for Major Surgery. 
  • Perioperative Right Ventricular Dysfunction: Analysis of Outcomes. 
  • Periprocedural Risk and Survival Associated With Implantable Cardioverter-Defibrillator Placement in Older Patients With Advanced Heart Failure. 
  • Permanent pacemaker use among patients with heart failure and preserved ejection fraction: Findings from the Acute Decompensated Heart Failure National Registry (ADHERE) National Registry. 
  • Persistent and reversible cardiac dysfunction among amateur marathon runners. 
  • Personalized Therapeutic Approach: Gun Control for Shotgun Therapy. 
  • Pexelizumab and infarct size in patients with acute myocardial infarction undergoing primary percutaneous coronary Intervention: a delayed enhancement cardiac magnetic resonance substudy from the APEX-AMI trial. 
  • Pharmacogenomic study of heart failure and candesartan response from the CHARM programme. 
  • Pharmacogenomics of Bucindolol in Atrial Fibrillation and Heart Failure. 
  • Pharmacologic Therapy for Heart Failure with Preserved Ejection Fraction. 
  • Pharmacological management of atrial fibrillation in patients with heart failure with reduced ejection fraction: review of current knowledge and future directions. 
  • Phase plane analysis of left ventricular hemodynamics. 
  • Phenomapping for novel classification of heart failure with preserved ejection fraction. 
  • Phenomapping for the Identification of Hypertensive Patients with the Myocardial Substrate for Heart Failure with Preserved Ejection Fraction. 
  • Phenomapping in heart failure with preserved ejection fraction: insights, limitations, and future directions. 
  • Phenotyping heart failure patients for iron deficiency and use of intravenous iron therapy: data from the Swedish Heart Failure Registry. 
  • Physical Activity, Quality of Life, and Biomarkers in Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction (from the NEAT-HFpEF Trial). 
  • Physical Activity, Subclinical Myocardial Injury, and Risk of Heart Failure Subtypes in Black Adults. 
  • Physical Function, Frailty, Cognition, Depression, and Quality of Life in Hospitalized Adults ≥60 Years With Acute Decompensated Heart Failure With Preserved Versus Reduced Ejection Fraction. 
  • Physical Functioning in Heart Failure With Preserved Ejection Fraction. 
  • Physiologic goal-directed therapy in the perioperative period: the volume prescription for high-risk patients. 
  • Physiological and psychological variables predict compliance to prescribed exercise therapy in patients recovering from myocardial infarction. 
  • Plantar flexion: an effective training for peripheral arterial disease. 
  • Plasma metabolites associated with functional and clinical outcomes in heart failure with reduced ejection fraction with and without type 2 diabetes. 
  • Plasma renin activity, response to aliskiren, and clinical outcomes in patients hospitalized for heart failure: the ASTRONAUT trial. 
  • Polygenic Score for β-Blocker Survival Benefit in European Ancestry Patients With Reduced Ejection Fraction Heart Failure. 
  • Polypharmacy in Heart Failure with Reduced Ejection Fraction: Progress, Not Problem. 
  • Polypharmacy in Palliative Care for Advanced Heart Failure: The PAL-HF Experience. 
  • Population Pharmacokinetics of Vericiguat in Patients With Heart Failure With Reduced Ejection Fraction: An Integrated Analysis. 
  • Population-Level Implications of Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure With Preserved Ejection Fraction in the US. 
  • Post-Traumatic Stress Disorder and Heart Failure in Men Within the Veteran Affairs Health System. 
  • Post-discharge haemodilution, congestion, and clinical outcomes among patients hospitalized for heart failure with reduced ejection fraction: results from the EVEREST trial. 
  • Poststress measurements of left ventricular function with gated perfusion SPECT: comparison with resting measurements by using a same-day perfusion-function protocol. 
  • Postural exercise abnormalities in symptomatic patients with mitral valve prolapse. 
  • Potassium Abnormalities Across the Spectrum of Heart Failure. 
  • Potential Mortality Reduction With Optimal Implementation of Angiotensin Receptor Neprilysin Inhibitor Therapy in Heart Failure. 
  • Potential cost-effectiveness of prophylactic use of the implantable cardioverter defibrillator or amiodarone after myocardial infarction. 
  • Potential impact of optimal implementation of evidence-based heart failure therapies on mortality. 
  • Practical Patient Care Considerations With Use of Vericiguat After Worsening Heart Failure Events. 
  • Pre-discharge and early post-discharge troponin elevation among patients hospitalized for heart failure with reduced ejection fraction: findings from the ASTRONAUT trial. 
  • Precipitating Clinical Factors, Heart Failure Characterization, and Outcomes in Patients Hospitalized With Heart Failure With Reduced, Borderline, and Preserved Ejection Fraction. 
  • Predicting Prognosis in Heart Failure: Important, But Easier Said Than Done. 
  • Predicting chronic left ventricular dysfunction 90 days after ST-segment elevation myocardial infarction: An Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) Substudy. 
  • Predicting significant coronary artery disease in patients with left ventricular dysfunction. 
  • Predicting survival after coronary revascularization for ischemic cardiomyopathy. 
  • Predicting the Development of Reduced Left Ventricular Ejection Fraction in Patients With Left Bundle Branch Block. 
  • Prediction and prevention of chemotherapy-induced cardiomyopathy: can it be done? 
  • Prediction of Left Ventricular Ejection Fraction Change Following Treatment With Sacubitril/Valsartan. 
  • Prediction of death and myocardial infarction by radionuclide angiocardiography in patients with suspected coronary artery disease. 
  • Prediction of myocardial perfusion abnormalities by quantitative regional function using a radionuclide angiography database: a comparison with wall motion analysis. 
  • Prediction of readmissions and mortality in patients with heart failure: lessons from the IMPEDANCE-HF extended trial. 
  • Predictive value of low relative lymphocyte count in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. 
  • Predictors and Changes in Cardiac Hemodynamics and Geometry With Transcatheter Aortic Valve Implantation. 
  • Predictors and Prognostic Implications of Incident Heart Failure in Patients With Prevalent Atrial Fibrillation. 
  • Predictors and progression of aortic stenosis in patients with preserved left ventricular ejection fraction. 
  • Predictors of Mortality by Sex and Race in Heart Failure With Preserved Ejection Fraction: ARIC Community Surveillance Study. 
  • Predictors of contemporary coronary artery bypass grafting outcomes. 
  • Predictors of inotrope use during separation from cardiopulmonary bypass. 
  • Predictors of mortality and outcomes of therapy in low-flow severe aortic stenosis: a Placement of Aortic Transcatheter Valves (PARTNER) trial analysis. 
  • Predictors of mortality in patients with chronic kidney disease and an implantable defibrillator: an EPGEN substudy. 
  • Predictors of outcome of myocarditis. 
  • Predictors of proarrhythmic effect in heart failure patients after 9-week hybrid comprehensive telerehabilitation and their influence on cardiovascular mortality in long-term follow-up: Subanalysis of the TELEREH-HF randomized clinical trial. 
  • Predictors of sudden cardiac death change with time after myocardial infarction: results from the VALIANT trial. 
  • Predictors of sustained ventricular arrhythmias in cardiac resynchronization therapy. 
  • Predisposition to arrhythmias: electrolytes, uremic fibrosis, other factors. 
  • Preliminary report on cardiac dysfunction after isolated traumatic brain injury. 
  • Preoperative Determinants of Quality of Life and Functional Capacity Response to Left Ventricular Assist Device Therapy. 
  • Preoperative Echocardiographic Differences and Transplant Outcomes Among Patients Receiving Simultaneous Liver-Kidney Versus Liver Transplant Alone. 
  • Preoperative determinants of postoperative costs associated with coronary artery bypass graft surgery. 
  • Presence of atrial fibrillation is independently associated with adverse outcomes in patients hospitalized with heart failure: an analysis of get with the guidelines-heart failure. 
  • Presence of mechanical dyssynchrony in Duchenne muscular dystrophy. 
  • Prevalence and Prognostic Significance of Left Ventricular Noncompaction in Patients Referred for Cardiac Magnetic Resonance Imaging. 
  • Prevalence and Prognostic Significance of Polyvascular Disease in Patients Hospitalized With Acute Decompensated Heart Failure: The ARIC Study. 
  • Prevalence and distribution of late gadolinium enhancement in a large population of patients with Duchenne muscular dystrophy: effect of age and left ventricular systolic function. 
  • Prevalence and prognostic impact of bundle branch block in patients with heart failure: evidence from the CHARM programme. 
  • Prevalence and prognostic impact of non-cardiac co-morbidities in heart failure outpatients with preserved and reduced ejection fraction: a community-based study. 
  • Prevalence and prognostic implications of electrocardiographic left ventricular hypertrophy in heart failure: evidence from the CHARM programme. 
  • Prevalence and prognostic importance of precipitating factors leading to heart failure hospitalization: recurrent hospitalizations and mortality. 
  • Prevalence of Prediabetes and Undiagnosed Diabetes in Patients with HFpEF and HFrEF and Associated Clinical Outcomes. 
  • Prevalence of symptomatic diastolic heart failure in patients hospitalized with cerebral or peripheral vascular disease. 
  • Prevalence, Profile, and Prognosis of Severe Obesity in Contemporary Hospitalized Heart Failure Trial Populations. 
  • Prevalent digoxin use and subsequent risk of death or hospitalization in ambulatory heart failure patients with a reduced ejection fraction-Findings from the Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) randomized controlled trial. 
  • Primary Prevention of Heart Failure in Women. 
  • Primary Results From the Understanding Outcomes With the S-ICD in Primary Prevention Patients With Low Ejection Fraction (UNTOUCHED) Trial. 
  • Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection Fraction. 
  • Prioritizing Quad Therapy and the Path Forward in Guideline-Directed Medical Therapy for Patients With Heart Failure With Reduced Ejection Fraction. 
  • Prioritizing prevention of de novo and worsening chronic heart failure. 
  • Pro-Inflammatory Biomarkers in Stable Versus Acutely Decompensated Heart Failure With Preserved Ejection Fraction. 
  • Probabilistic Readjudication of Heart Failure Hospitalization Events in the PARAGON-HF Study. 
  • Prognosis after change in left ventricular ejection fraction during mental stress testing in patients with stable coronary artery disease. 
  • Prognosis by measurements of left ventricular function during exercise. Duke Noninvasive Research Working Group. 
  • Prognosis for patients with heart failure and reduced ejection fraction with and without diabetes: A 7 year nationwide veteran administration analysis. 
  • Prognosis in cardiogenic shock after acute myocardial infarction in the interventional era. 
  • Prognostic Impact of Cardiac Diastolic Function and Coronary Microvascular Function on Cardiovascular Death. 
  • Prognostic Impact of Coronary Flow Reserve in Patients With Reduced Left Ventricular Ejection Fraction. 
  • Prognostic Implications of Blunted Feature-Tracking Global Longitudinal Strain During Vasodilator Cardiovascular Magnetic Resonance Stress Imaging. 
  • Prognostic Implications of Congestion on Physical Examination Among Contemporary Patients With Heart Failure and Reduced Ejection Fraction: PARADIGM-HF. 
  • Prognostic Interplay Between COVID-19 and Heart Failure With Reduced Ejection Fraction. 
  • Prognostic Role of Prior Heart Failure Hospitalization Among Patients Hospitalized for Worsening Chronic Heart Failure. 
  • Prognostic Value of Albuminuria and Influence of Spironolactone in Heart Failure With Preserved Ejection Fraction. 
  • Prognostic Value of Vasodilator Stress Cardiac Magnetic Resonance Imaging: A Multicenter Study With 48 000 Patient-Years of Follow-up. 
  • Prognostic effect of bundle branch block related to coronary artery bypass grafting. 
  • Prognostic importance of pathophysiologic markers in patients with heart failure and preserved ejection fraction. 
  • Prognostic indicators from radionuclide angiography in medically treated patients with coronary artery disease. 
  • Prognostic significance of anaemia in patients with heart failure with preserved and reduced ejection fraction: results from the MAGGIC individual patient data meta-analysis. 
  • Prognostic significance of depression in blacks with heart failure: insights from Heart Failure: a Controlled Trial Investigating Outcomes of Exercise Training. 
  • Prognostic significance of exercise-induced complex ventricular arrhythmias in coronary artery disease with normal and abnormal left ventricular ejection fraction. 
  • Prognostic significance of nonsustained ventricular tachycardia identified postoperatively after coronary artery bypass surgery in patients with left ventricular dysfunction. 
  • Prognostic significance of obstructive coronary artery disease in patients admitted with acute decompensated heart failure: the ARIC study community surveillance. 
  • Prognostic significance of serum total cholesterol and triglyceride levels in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial). 
  • Prognostic value of a coronary artery jeopardy score. 
  • Prognostic value of anxiety and depression in patients with chronic heart failure. 
  • Prognostic value of congestive heart failure history in patients undergoing percutaneous coronary interventions. 
  • Prognostic value of monocyte count in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial). 
  • Prognostic value of routine cardiac magnetic resonance assessment of left ventricular ejection fraction and myocardial damage: an international, multicenter study. 
  • Prognostic value of stress myocardial perfusion positron emission tomography: results from a multicenter observational registry. 
  • Progression of Myocardial Fibrosis in Nonischemic DCM and Association With Mortality and Heart Failure Outcomes. 
  • Progression of cardiac structure and function in people with human immunodeficiency virus. 
  • Projected Clinical Benefits of Implementation of SGLT-2 Inhibitors Among Medicare Beneficiaries Hospitalized for Heart Failure. 
  • Prolonged QRS in Heart Failure With Preserved Ejection Fraction: Risk Marker and Therapeutic Target? 
  • Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. 
  • Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. 
  • Prophylactic levosimendan in patients with low ejection fraction undergoing coronary artery bypass grafting: A pooled analysis of two multicentre randomised controlled trials. 
  • Proportion of patients followed in a specialized heart failure clinic needing an implantable cardioverter defibrillator as determined by applying different trial eligibility criteria. 
  • Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI): design and baseline characteristics. 
  • Prospective, randomized trial comparing blood and oxygenated crystalloid cardioplegia in reoperative coronary artery bypass grafting. 
  • Protein biomarkers of cardiac remodeling and inflammation associated with HFpEF and incident events. 
  • Psychometric Evaluation of the Kansas City Cardiomyopathy Questionnaire in Men and Women With Heart Failure. 
  • Psychosocial Factors, Exercise Adherence, and Outcomes in Heart Failure Patients: Insights From Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION). 
  • Pulmonary function and adverse cardiovascular outcomes: Can cardiac function explain the link? 
  • Pulmonary hypertension and long-term mortality in aortic and mitral regurgitation. 
  • Pulsatile hemodynamic effects of candesartan in patients with chronic heart failure: the CHARM Program. 
  • Pulsus alternans: a visual clue to a grave disorder! 
  • Pure annular dilation as a cause of mitral regurgitation: a clinically distinct entity of female heart disease. 
  • Putting the "Optimal" in Optimal Medical Therapy. 
  • Quality of life and economic outcomes with surgical ventricular reconstruction in ischemic heart failure: results from the Surgical Treatment for Ischemic Heart Failure trial. 
  • Quality of life and treatment preference for ventricular assist device therapy in ambulatory advanced heart failure: A report from the REVIVAL study. 
  • Quality of life in heart failure with preserved ejection fraction: importance of obesity, functional capacity, and physical inactivity. 
  • Quality outcomes, healthcare resource utilization and costs in Medicare patients with chronic heart failure with reduced ejection fraction with and without a worsening event. 
  • Quantification of aortic regurgitation by real-time 3-dimensional echocardiography in a chronic animal model: computation of aortic regurgitant volume as the difference between left and right ventricular stroke volumes. 
  • Quantification of infarct size by 201Tl single-photon emission computed tomography during acute myocardial infarction in humans. Comparison with enzymatic estimates. 
  • Quantification of regional myocardial dysfunction after acute ischemic injury. 
  • Quantification of the contractile response to injury: assessment of the work-length relationship in the intact heart. 
  • Quantifying Myocardial Contractility Changes Using Ultrasound-Based Shear Wave Elastography. 
  • Quantifying the Impact of Atrial Fibrillation on Heart Failure-Related Patient-Reported Outcomes in the Utah mEVAL Program. 
  • Quantitative Blood Volume Analysis and Hemodynamic Measures of Vascular Compliance in Patients With Worsening Heart Failure. 
  • Quantitative echocardiographic assessment of regional wall motion and left ventricular asynchrony with color kinesis in cardiac surgery patients. 
  • Race- and Gender-Based Differences in Cardiac Structure and Function and Risk of Heart Failure. 
  • Race/Ethnic Differences in Outcomes Among Hospitalized Medicare Patients With Heart Failure and Preserved Ejection Fraction. 
  • Racial Differences and Temporal Obesity Trends in Heart Failure with Preserved Ejection Fraction. 
  • Racial and Ethnic Differences in Biomarkers, Health Status, and Cardiac Remodeling in Patients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/Valsartan. 
  • Racial differences in the outcomes of patients with diastolic heart failure. 
  • Racial disparity in the utilization of implantable-cardioverter defibrillators among patients with prior myocardial infarction and an ejection fraction of  
  • Radial artery pulse pressure variation correlates with brachial artery peak velocity variation in ventilated subjects when measured by internal medicine residents using hand-carried ultrasound devices. 
  • Radiographic and Clinical Predictors of Cardiac Dysfunction Following Isolated Traumatic Brain Injury. 
  • Randomized Evaluation of Heart Failure With Preserved Ejection Fraction Patients With Acute Heart Failure and Dopamine: The ROPA-DOP Trial. 
  • Randomized Placebo-Controlled Trial of Ferric Carboxymaltose in Heart Failure With Iron Deficiency: Rationale and Design. 
  • Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia. 
  • Randomized evaluation of coronary angioplasty for early TIMI 2 flow after thrombolytic therapy for the treatment of acute myocardial infarction: a new look at an old study. The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. 
  • Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. 
  • Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial. 
  • Rapid ventricular filling in left ventricular hypertrophy: I. Physiologic hypertrophy. 
  • Rate pressure product and the components of heart rate and systolic blood pressure in hospitalized heart failure patients with preserved ejection fraction: Insights from ASCEND-HF. 
  • Rate-Adaptive Pacing for Heart Failure With Preserved Ejection Fraction. 
  • Rationale and Design of the VITALITY-HFpEF Trial. 
  • Rationale and design for the development of a novel nitroxyl donor in patients with acute heart failure. 
  • Rationale and design of a randomized controlled trial of allogeneic mesenchymal stem cells in patients with nonischemic cardiomyopathy. 
  • Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST). 
  • Rationale and design of the phase 2b clinical trials to study the effects of the partial adenosine A1-receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced (PANTHEON) and preserved (PANACHE) ejection fraction. 
  • Re-evaluating the significance of the dive response during voluntary surface apneas in the bottlenose dolphin, Tursiops truncatus. 
  • Reactive hyperemia is associated with adverse clinical outcomes in heart failure. 
  • Real-time 3-dimensional echocardiography for quantification of the difference in left ventricular versus right ventricular stroke volume in a chronic animal model study: Improved results using C-scans for quantifying aortic regurgitation. 
  • Real-time three-dimensional echocardiography for determining right ventricular stroke volume in an animal model of chronic right ventricular volume overload. 
  • Real-time three-dimensional echocardiography to construct clinically ready, load-independent indices of myocardial contractile performance. 
  • Reassessment of Cardiac Function and Implantable Cardioverter-Defibrillator Use Among Medicare Patients With Low Ejection Fraction After Myocardial Infarction. 
  • Reclassifying heart failure: time for disruptive innovation? 
  • Recovery of left ventricular function is associated with improved outcomes in LVAD recipients. 
  • Recovery of systolic and diastolic left ventricular function after a 60-second coronary arterial occlusion during percutaneous transluminal coronary angioplasty for angina pectoris. 
  • Reduced ejection fraction, sudden cardiac death, and heart failure death in the mode selection trial (MOST): implications for device selection in elderly patients with sinus node disease. 
  • Reduced left ventricular filling following blood volume extraction does not result in compensatory augmentation of cardiac mechanics. 
  • Regional Adipose Distribution and its Relationship to Exercise Intolerance in Older Obese Patients Who Have Heart Failure With Preserved Ejection Fraction. 
  • Regional adiposity and heart failure with preserved ejection fraction. 
  • Regulation of stroke volume during submaximal and maximal upright exercise in normal man. 
  • Rehabilitation Intervention in Older Patients With Acute Heart Failure With Preserved Versus Reduced Ejection Fraction. 
  • Relation between premature ventricular contraction site of origin (defined by radionuclide phase analysis) and subsequent left ventricular function. 
  • Relation between radionuclide angiographic regional ejection fraction and left ventricular regional ischemia in awake dogs. 
  • Relation between reversal of diastolic creep and recovery of systolic function after ischemic myocardial injury in conscious dogs. 
  • Relation between the number of image planes and the accuracy of three-dimensional echocardiography for measuring left ventricular volumes and ejection fraction. 
  • Relation of Elevated Heart Rate in Patients With Heart Failure With Reduced Ejection Fraction to One-Year Outcomes and Costs. 
  • Relation of Low Normal Left Ventricular Ejection Fraction to Heart Failure Hospitalization in Blacks (From the Jackson Heart Study). 
  • Relation of Volume Overload to Clinical Outcomes in Acute Heart Failure (From ASCEND-HF). 
  • Relation of anemia to diastolic heart failure and the effect on outcome. 
  • Relation of ejection fraction and inducible ventricular tachycardia to mode of death in patients with coronary artery disease: an analysis of patients enrolled in the multicenter unsustained tachycardia trial. 
  • Relation of frequency and severity of mitral regurgitation to survival among patients with left ventricular systolic dysfunction and heart failure. 
  • Relation of left atrial function with exercise capacity and muscle endurance in patients with heart failure. 
  • Relation of serum levels of mast cell tryptase of left ventricular systolic function, left ventricular volume or congestive heart failure. 
  • Relation of serum magnesium levels and postdischarge outcomes in patients hospitalized for heart failure (from the EVEREST Trial). 
  • Relation of serum uric acid levels and outcomes among patients hospitalized for worsening heart failure with reduced ejection fraction (from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan trial). 
  • Relation of size of secondary ventricles to exercise performance in children after fontan operation. 
  • Relation of ventricular premature complexes during recovery from a myocardial perfusion exercise stress test to myocardial ischemia. 
  • Relationship Between Hospital Characteristics and Early Adoption of Angiotensin-Receptor/Neprilysin Inhibitor Among Eligible Patients Hospitalized for Heart Failure. 
  • Relationship between accurate auscultation of a clinically useful third heart sound and level of experience. 
  • Relationship between antecedent angina pectoris and short-term prognosis after thrombolytic therapy for acute myocardial infarction. Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. 
  • Relationship between galectin-3 levels and mineralocorticoid receptor antagonist use in heart failure: analysis from HF-ACTION. 
  • Relationship between left ventricular ejection fraction and cardiovascular outcomes following hospitalization for heart failure: insights from the RELAX-AHF-2 trial. 
  • Relationship between physical capacity and depression in heart failure patients undergoing hybrid comprehensive telerehabilitation vs. usual care: subanalysis from the TELEREH-HF Randomized Clinical Trial. 
  • Relationship between sex, ejection fraction, and B-type natriuretic peptide levels in patients hospitalized with heart failure and associations with inhospital outcomes: findings from the Get With The Guideline-Heart Failure Registry. 
  • Relationship between ventricular repolarization parameters and the inducibility of ventricular arrhythmias during electrophysiological study in patients with coronary artery disease. 
  • Relationship of Right Ventricular Size and Function with Respiratory Status in Duchenne Muscular Dystrophy. 
  • Relationship of physical function with quality of life in older patients with acute heart failure. 
  • Relationship of technetium-99m tetrofosmin-gated rest single-photon emission computed tomography myocardial perfusion imaging to death and hospitalization in heart failure patients: results from the nuclear ancillary study of the HF-ACTION trial. 
  • Relationships between changes in patient-reported health status and functional capacity in outpatients with heart failure. 
  • Relaxin-2 and Soluble Flt1 Levels in Peripartum Cardiomyopathy: Results of the Multicenter IPAC Study. 
  • Renal Dysfunction in Heart Failure With Preserved Ejection Fraction: Insights From the RELAX Trial. 
  • Renal Function and Exercise Training in AmbulatoryHeart Failure Patients With a Reduced Ejection Fraction. 
  • Renal effects of guideline-directed medical therapies in heart failure: a consensus document from the Heart Failure Association of the European Society of Cardiology. 
  • Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the VICTORIA (Vericiguat Global Study in Subjects with HFrEF) trial. 
  • Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. 
  • Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. 
  • Renin-angiotensin blockade in heart failure with preserved ejection fraction: a systematic review and meta-analysis. 
  • Reply: Blood Pressure and Lack of Association With Treatment Benefits of Dapagliflozin in HFpEF and HFmrEF. 
  • Reply: Diuretic Strategies and Renal Dysfunction in Heart Failure With Preserved Ejection Fraction. 
  • Reply: Heart Failure With Preserved Ejection Fraction: Types 1 and 2? 
  • Reply: Revisited Metformin Therapy in Heart Failure With Preserved Ejection Fraction. 
  • Reply: Titration of Guideline-Directed Medical Therapy Improves Patient-Centered Outcomes in Heart Failure With Reduced Ejection Fraction. 
  • Representation of black patients in randomized clinical trials of heart failure with reduced ejection fraction. 
  • Representativeness of the PIONEER-HF Clinical Trial Population in Patients Hospitalized With Heart Failure and Reduced Ejection Fraction. 
  • Representativeness of the VICTORIA Trial Population in Clinical Practice: Analysis of the PINNACLE Registry. 
  • Reproducibility of Left Ventricular Dimension Versus Area Versus Volume Measurements in Pediatric Patients With Dilated Cardiomyopathy. 
  • Reproducibility of peak oxygen uptake and other cardiopulmonary exercise testing parameters in patients with heart failure (from the Heart Failure and A Controlled Trial Investigating Outcomes of exercise traiNing). 
  • Rescue of Pressure Overload-Induced Heart Failure by Estrogen Therapy. 
  • Response to preventive cardiac resynchronization therapy in patients with ischaemic and nonischaemic cardiomyopathy in MADIT-CRT. 
  • Resting ventricular-vascular function and exercise capacity in heart failure with preserved ejection fraction: a RELAX trial ancillary study. 
  • Rethinking Revascularization in Left Ventricular Systolic Dysfunction. 
  • Revascularization improves survival in ischemic cardiomyopathy regardless of electrocardiographic criteria for prior small-to-medium myocardial infarcts. 
  • Reverse Cardiac Remodeling Following Initiation of Sacubitril/Valsartan in Patients With Heart Failure With and Without Diabetes. 
  • Review of advanced heart failure device diagnostics examined in clinical trials and the potential benefit from monitoring capabilities. 
  • Review: In CAD without HF, RAS inhibitors reduce deaths more than placebo but not active control. 
  • Rhythm Control Versus Rate Control in Patients With Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction: Insights From Get With The Guidelines-Heart Failure. 
  • Right Ventricular Abnormalities on Cardiovascular Magnetic Resonance Imaging in Patients With Sarcoidosis. 
  • Right and left ventricular diastolic pressure-volume relations: a comprehensive review. 
  • Right and left ventricular performance during and after abdominal aortic aneurysm repair. 
  • Right atrial volume by cardiovascular magnetic resonance predicts mortality in patients with heart failure with reduced ejection fraction. 
  • Right heart dysfunction after left ventricular assist device implantation: a comparison of the pulsatile HeartMate I and axial-flow HeartMate II devices. 
  • Right ventricular diastolic relaxation in conscious dog models of pressure overload, volume overload, and ischemia. 
  • Right ventricular dysfunction and the incidence of implantable cardioverter-defibrillator therapies. 
  • Right ventricular hypertrophy with early dysfunction: A proteomics study in a neonatal model. 
  • Right ventricular lead location and outcomes among patients with cardiac resynchronization therapy: A meta-analysis. 
  • Right ventricular morphology and systolic function in left ventricular noncompaction cardiomyopathy. 
  • Right ventricular volumes are rarely right and are right hard to do. 
  • Right, but not left, bundle branch block is associated with large anteroseptal scar. 
  • Right-Sided Cardiac Dysfunction in Heart Failure With Preserved Ejection Fraction and Worsening Renal Function. 
  • Risk Adjustment Model for Preserved Health Status in Patients With Heart Failure and Reduced Ejection Fraction: The CHAMP-HF Registry. 
  • Risk assessment to predict arterial and venous events in patients undergoing percutaneous coronary intervention. 
  • Risk factors for hospital admission among older persons with newly diagnosed heart failure: findings from the Cardiovascular Health Study. 
  • Risk stratification for adverse economic outcomes in cardiac surgery. 
  • Role of Diastolic Function in Preserved Exercise Capacity in Patients with Reduced Ejection Fractions. 
  • Role of right ventricular and pulmonary functional abnormalities in limiting exercise capacity in adults with congenital heart disease. 
  • Roles for SGLT2 Inhibitors in Cardiorenal Disease. 
  • SGLT-2 Inhibitors for Patients with Heart Failure: What Have We Learned Recently? 
  • SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. 
  • Sacubitril/Valsartan Adherence and Postdischarge Outcomes Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction. 
  • Sacubitril/Valsartan Initiation and Postdischarge Adherence Among Patients Hospitalized for Heart Failure. 
  • Sacubitril/Valsartan Therapy for AF and HFpEF: Is the Glass Half Empty or Half Full? 
  • Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction: Rationale and Design of the LIFE Trial. 
  • Sacubitril/valsartan versus ramipril for patients with acute myocardial infarction: win-ratio analysis of the PARADISE-MI trial. 
  • Safety and efficacy of inferior vena caval occlusion to rapidly alter ventricular loading conditions in idiopathic dilated cardiomyopathy. 
  • Safety and efficacy of the partial adenosine A1 receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced ejection fraction: a phase IIb, randomized, double-blind, placebo-controlled trial. 
  • Safety of symptom-limited cardiopulmonary exercise testing in patients with chronic heart failure due to severe left ventricular systolic dysfunction. 
  • Sarcopenic obesity and the pathogenesis of exercise intolerance in heart failure with preserved ejection fraction. 
  • Sequential Evaluation of NT-proBNP in Heart Failure: Insights Into Clinical Outcomes and Efficacy of Vericiguat. 
  • Serelaxin in acute heart failure patients with preserved left ventricular ejection fraction: results from the RELAX-AHF trial. 
  • Serial assessment of ventricular performance after valve replacement for aortic stenosis. 
  • Serial changes in left ventricular ejection fraction in the early hours after aortocoronary bypass grafting. 
  • Serial evaluation of right ventricular dysfunction associated with acute inferior myocardial infarction. 
  • Serial left ventricular performance evaluated by cardiac catheterization before, immediately after and at 6 months after balloon aortic valvuloplasty. 
  • Serial prognostic capabilities of electrocardiographic indices of infarcted and hibernating myocardium in predicting short- and long-term outcome following coronary artery bypass surgery. 
  • Serum Osmolality and Postdischarge Outcomes After Hospitalization for Heart Failure. 
  • Serum insulin-like growth factor-1 and its binding protein-7: potential novel biomarkers for heart failure with preserved ejection fraction. 
  • Serum uric acid, influence of sacubitril-valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction: PARAGON-HF. 
  • Severity of Remodeling, Myocardial Viability, and Survival in Ischemic LV Dysfunction After Surgical Revascularization. 
  • Sex Differences in Characteristics, Outcomes, and Treatment Response With Dapagliflozin Across the Range of Ejection Fraction in Patients With Heart Failure: Insights From DAPA-HF and DELIVER. 
  • Sex Differences in Clinical Course and Patient-Reported Outcomes Among Patients Hospitalized for Heart Failure. 
  • Sex Differences in the Management and Outcomes of Heart Failure With Preserved Ejection Fraction in Patients Presenting to the Emergency Department With Acute Heart Failure. 
  • Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. 
  • Sex differences in heart mitochondria regulate diastolic dysfunction. 
  • Sex differences in in-hospital mortality in acute decompensated heart failure with reduced and preserved ejection fraction. 
  • Sex-Based Differences in Outcomes After Mitral Valve Surgery for Severe Ischemic Mitral Regurgitation: From the Cardiothoracic Surgical Trials Network. 
  • Sex-Differences in Cause of Death for Patients Hospitalized for Heart Failure With Reduced Versus Preserved Ejection Fraction (from the ASCEND-HF Trial). 
  • Sex-Related Differences in Heart Failure With Preserved Ejection Fraction. 
  • Sex-related differences in the normal cardiac response to upright exercise. 
  • Sex-specific acute heart failure phenotypes and outcomes from PROTECT. 
  • Should His Bundle Pacing Be Preferred over Cardiac Resynchronization Therapy Following Atrioventricular Junction Ablation? 
  • Sildenafil Treatment in Heart Failure With Preserved Ejection Fraction: Targeted Metabolomic Profiling in the RELAX Trial. 
  • Sildenafil exposure and hemodynamic effect after Fontan surgery. 
  • Single-photon emission computed tomography myocardial perfusion imaging and the risk of sudden cardiac death in patients with coronary disease and left ventricular ejection fraction>35%. 
  • Size Matters: Normalization of QRS Duration to Left Ventricular Dimension Improves Prediction of Long-Term Cardiac Resynchronization Therapy Outcome. 
  • Skeletal muscle abnormalities and exercise intolerance in older patients with heart failure and preserved ejection fraction. 
  • Skeletal muscle abnormalities in heart failure with preserved ejection fraction. 
  • Sleep Breathing Disorders in Heart Failure. 
  • Sodium-Glucose Cotransporter 2 Inhibitors and Cardiac Remodeling. 
  • Sodium-glucose co-transporter 2 inhibitors as an early, first-line therapy in patients with heart failure and reduced ejection fraction. 
  • Sodium-glucose cotransporter 2 inhibitors for heart failure with mildly reduced or preserved ejection fraction: time to deliver implementation. 
  • Soluble ST2 in ambulatory patients with heart failure: Association with functional capacity and long-term outcomes. 
  • Soluble guanylate cyclase stimulators in patients with heart failure with reduced ejection fraction across the risk spectrum. 
  • Spironolactone in Acute Heart Failure Patients With Renal Dysfunction and Risk Factors for Diuretic Resistance: From the ATHENA-HF Trial. 
  • Spironolactone metabolite concentrations in decompensated heart failure: insights from the ATHENA-HF trial. 
  • Splanchnic Nerve Block Mediated Changes in Stressed Blood Volume in Heart Failure. 
  • Splanchnic Nerve Block for Chronic Heart Failure. 
  • Statins and Exercise Training Response in Heart Failure Patients: Insights From HF-ACTION. 
  • Stroke volume calculation by esophageal Doppler integrates velocity over time and multiplies this "area under the curve" by the cross sectional area of the aorta. 
  • Sudden Cardiac Death in Patients With Ischemic Heart Failure Undergoing Coronary Artery Bypass Grafting: Results From the STICH Randomized Clinical Trial (Surgical Treatment for Ischemic Heart Failure). 
  • Sudden Death After Hospitalization for Heart Failure With Reduced Ejection Fraction (from the EVEREST Trial). 
  • Sudden cardiac death after acute heart failure hospital admission: insights from ASCEND-HF. 
  • Sudden cardiac death in patients with myocarditis: Evaluation, risk stratification, and management. 
  • Suppression of Tumorigenicity 2 in Heart Failure With Preserved Ejection Fraction. 
  • Surgical ablation of the right greater splanchnic nerve for the treatment of heart failure with preserved ejection fraction: first-in-human clinical trial. 
  • Surrogate end points in heart failure trials. 
  • Survival and cardiac event rates in the first year after emergency coronary angioplasty for acute myocardial infarction. 
  • Survival of coronary artery disease patients with stable pain and normal left ventricular function treated medically or surgically at Duke University. 
  • Survival with cardiac-resynchronization therapy in mild heart failure. 
  • Synchronized diaphragmatic stimulation for heart failure using the VisONE system: a first-in-patient study. 
  • Syncope predicts the outcome of cardiomyopathy patients: analysis of the SCD-HeFT study. 
  • Systolic Blood Pressure in Heart Failure With Preserved Ejection Fraction Treated With Sacubitril/Valsartan. 
  • Systolic blood pressure and cardiovascular outcomes in heart failure with preserved ejection fraction: an analysis of the TOPCAT trial. 
  • Systolic time interval characteristics in children with Duchenne's progressive muscular dystrophy. 
  • T wave alternans: a marker of myocardial instability. 
  • Tackling Inflammation in Heart Failure With Preserved Ejection Fraction: Resurrection of Vagus Nerve Stimulation? 
  • Target Doses of Heart Failure Medical Therapy and Blood Pressure: Insights From the CHAMP-HF Registry. 
  • Targeting Comorbidities in Elderly Patients With Heart Failure: The OPTIMIZE-HFPEF Trial. 
  • Targeting Natriuretic Peptide Levels in Heart Failure with Therapy: Does "X" Really Mark the Spot? 
  • Temporal Trends and Factors Associated With Cardiac Rehabilitation Participation Among Medicare Beneficiaries With Heart Failure. 
  • Temporal Trends and Prognosis of Physical Examination Findings in Patients With Acute Decompensated Heart Failure: The ARIC Study Community Surveillance. 
  • Temporal Trends of Digoxin Use in Patients Hospitalized With Heart Failure: Analysis From the American Heart Association Get With The Guidelines-Heart Failure Registry. 
  • Temporal trends and factors associated with diabetes mellitus among patients hospitalized with heart failure: Findings from Get With The Guidelines-Heart Failure registry. 
  • Temporal trends and predictors in the use of aldosterone antagonists post-acute myocardial infarction. 
  • Temporal trends in risk profiles among patients hospitalized for heart failure. 
  • Ten-Year Outcomes After Coronary Artery Bypass Grafting According to Age in Patients With Heart Failure and Left Ventricular Systolic Dysfunction: An Analysis of the Extended Follow-Up of the STICH Trial (Surgical Treatment for Ischemic Heart Failure). 
  • Testing for Coronary Artery Disease in Older Patients With New-Onset Heart Failure: Findings From Get With The Guidelines-Heart Failure. 
  • Testosterone supplementation in heart failure: a meta-analysis. 
  • The Association Between Beta-blocker and Renin-Angiotensin System Inhibitor Use After Heart Failure With Reduced Ejection Fraction Hospitalization and Outcomes in Older Patients. 
  • The Association of Digital Health Application Use With Heart Failure Care and Outcomes: Insights From CONNECT-HF. 
  • The Association of a classical left bundle Branch Block Contraction Pattern by vendor-independent strain echocardiography and outcome after cardiac resynchronization therapy. 
  • The Athena trials: Autologous adipose-derived regenerative cells for refractory chronic myocardial ischemia with left ventricular dysfunction. 
  • The Axillary Intra-Aortic Balloon Pump as a Bridge to Recovery Allows Early Ambulation in Long-Term Use: Case Series and Literature Review. 
  • The Effects of Angiotensin Receptor-Neprilysin Inhibition on Major Coronary Events in Patients With Acute Myocardial Infarction: Insights From the PARADISE-MI Trial. 
  • The Impact of Depression on Outcomes in Patients With Heart Failure and Reduced Ejection Fraction Treated in the GUIDE-IT Trial. 
  • The Incidence and Consequence of Prosthesis-Patient Mismatch After Surgical Aortic Valve Replacement. 
  • The Maximally Tolerated Dose: The Key Context for Interpreting Subtarget Medication Dosing for Heart Failure. 
  • The NHLBI Study on Long-terM OUtcomes after the Multisystem Inflammatory Syndrome In Children (MUSIC): Design and Objectives. 
  • The Prevalence, Correlates, and Impact on Cardiac Mortality of Right Ventricular Dysfunction in Nonischemic Cardiomyopathy. 
  • The Role for Cardiovascular Remodeling in Cardiovascular Outcomes. 
  • The S1103Y cardiac sodium channel variant is associated with implantable cardioverter-defibrillator events in blacks with heart failure and reduced ejection fraction. 
  • The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. 
  • The STICH trial: evidence-based conclusions. 
  • The Use of Sacubitril/Valsartan for Hospitalized Heart Failure-Why Do We Care About Cost and Value? 
  • The Valsalva maneuver: a bedside "biomarker" for heart failure. 
  • The Value of Left Ventricular Support in Patients With Reduced Left Ventricular Function Undergoing Extensive Revascularization: An Analysis From the PROTECT-II Randomized Trial. 
  • The association of accelerated epigenetic age with all-cause mortality in cardiac catheterization patients as mediated by vascular and cardiometabolic outcomes. 
  • The association of improvement in left ventricular ejection fraction with outcomes in patients with heart failure with reduced ejection fraction: data from CHAMP-HF. 
  • The association of left ventricular ejection fraction with clinical outcomes after myocardial infarction: Findings from the Acute Coronary Treatment and Intervention Outcomes Network (ACTION) Registry-Get With the Guidelines (GWTG) Medicare-linked database. 
  • The authors' reply to the letter from Kerkhof et al entitled 'The importance of (measuring) the end-systolic volume index in predicting survival'. 
  • The burden of non-cardiac comorbidities and association with clinical outcomes in an acute heart failure trial - insights from ASCEND-HF. 
  • The cGMP signaling pathway as a therapeutic target in heart failure with preserved ejection fraction. 
  • The congestion score: a simple tool for a complicated disease? 
  • The continuous heart failure spectrum: moving beyond an ejection fraction classification. 
  • The effect of Aliskiren on exercise capacity in older patients with heart failure and preserved ejection fraction: A randomized, placebo-controlled, double-blind trial. 
  • The effect of PEEP on left ventricular diastolic dimensions and systolic performance following myocardial revascularization. 
  • The effect of intra-aortic balloon counterpulsation on left ventricular functional recovery early after acute myocardial infarction: a randomized experimental magnetic resonance imaging study. 
  • The effect of the cardiac myosin activator, omecamtiv mecarbil, on right ventricular structure and function in chronic systolic heart failure (COSMIC-HF). 
  • The effects of acute afterload change on systolic ventricular function in conscious dogs with normal vs. failing hearts. 
  • The effects of airway pressure on cardiac function in intact dogs and man. 
  • The effects of coronary revascularization on left ventricular function in ischemic heart disease. 
  • The effects of dopamine on myocardial functional recovery after reversible ischemic injury. 
  • The effects of exercise on cardiovascular biomarkers in patients with chronic heart failure. 
  • The end-systolic pressure-volume relationship in conscious dogs. 
  • The evolution of medical and surgical therapy for coronary artery disease. A 15-year perspective. 
  • The gene expression profile of patients with new-onset heart failure reveals important gender-specific differences. 
  • The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. 
  • The impact of chronic obstructive pulmonary disease in patients hospitalized for worsening heart failure with reduced ejection fraction: an analysis of the EVEREST Trial. 
  • The impact of intravenous fluid administration on complication rates in bowel surgery within an enhanced recovery protocol: a randomized controlled trial. 
  • The impact of race on utilization of durable left ventricular assist device therapy in patients with advanced heart failure. 
  • The impact of statistical adjustment on economic profiles of interventional cardiologists. 
  • The incidence and functional consequences of RT-associated cardiac perfusion defects. 
  • The mechanical and hemodynamic effects of left ventricular pacing in heart failure with preserved ejection fraction and left bundle branch block. 
  • The pediatric heart network's study on long-term outcomes of children with HLHS and the impact of Norwood Shunt type in the single ventricle reconstruction trial cohort (SVRIII): Design and adaptations. 
  • The problem of decompensated heart failure: nomenclature, classification, and risk stratification. 
  • The prognostic importance of comorbidity for mortality in patients with stable coronary artery disease. 
  • The prognostic significance of heart rate in patients hospitalized for heart failure with reduced ejection fraction in sinus rhythm: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study With Tolvaptan) trial. 
  • The relationship between baseline and follow-up left ventricular ejection fraction with adverse events among primary prevention ICD patients. 
  • The relationship between immediate outcome after cardiac surgery, homogeneous cardioplegia delivery, and ejection fraction. 
  • The relationship between left ventricular ejection fraction and mortality in patients with acute heart failure: insights from the ASCEND-HF Trial. 
  • The reproducibility and absolute values of echocardiographic measurements of left ventricular size and function in children are algorithm dependent. 
  • The role of atrial fibrillation catheter ablation in patients with heart failure. 
  • The role of cytoprotective cytokines in cardiac ischemia/reperfusion injury. 
  • The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. 
  • The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. 
  • The use of radionuclide angiography in the diagnosis of coronary artery disease--a logistic regression analysis. 
  • Therapy for heart failure with preserved ejection fraction: current status, unique challenges, and future directions. 
  • Three-dimensional echocardiography improves accuracy and compensates for sonographer inexperience in assessment of left ventricular ejection fraction. 
  • Time to Clinical Benefit of Dapagliflozin in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Secondary Analysis of the DELIVER Randomized Clinical Trial. 
  • Time to Quadruple Guideline-Directed Medical Therapy as a Key Performance Measure for Heart Failure. 
  • Timing and Causes of Readmission After Acute Heart Failure Hospitalization-Insights From the Heart Failure Network Trials. 
  • Tissue plasminogen activator: Toronto (TPAT) placebo-controlled randomized trial in acute myocardial infarction. 
  • Titration of Medical Therapy for Heart Failure With Reduced Ejection Fraction. 
  • Titration of medical therapy and clinical outcomes among patients with heart failure with reduced ejection fraction: Findings from the HF-ACTION trial. 
  • Titration of medications and outcomes in multi-ethnic heart failure cohorts (with reduced ejection fraction) from Singapore and New Zealand. 
  • Tobacco smoking in patients with heart failure and coronary artery disease: A 20-year experience at Duke University Medical Center. 
  • Tolerability and safety barriers to sodium-glucose cotransporter 2 inhibitor initiation in heart failure with reduced ejection fraction. 
  • Torsemide Versus Furosemide in Patients With Acute Heart Failure (from the ASCEND-HF Trial). 
  • Trained and supervised physician assistants can safely perform diagnostic cardiac catheterization with coronary angiography. 
  • Trajectory of Congestion Metrics by Ejection Fraction in Patients With Acute Heart Failure (from the Heart Failure Network). 
  • Trajectory of Decongestion and Mortality in Young Adults with Acute Heart Failure. 
  • Transapical Transcatheter Aortic Valve Replacement Is Associated With Increased Cardiac Mortality in Patients With Left Ventricular Dysfunction: Insights From the PARTNER I Trial. 
  • Transcardiopulmonary vs pulmonary arterial thermodilution methods for hemodynamic monitoring of burned patients. 
  • Transcatheter aortic valve replacement and standard therapy in inoperable patients with aortic stenosis and low EF. 
  • Transitional adherence and persistence in the use of aldosterone antagonist therapy in patients with heart failure. 
  • Transluminal catheter reperfusion: a new technique to reestablish blood flow after coronary occlusion during percutaneous transluminal coronary angioplasty. 
  • Transpulmonary lactate gradient after hypothermic cardiopulmonary bypass. 
  • Transthoracic impedance compared to magnetic resonance imaging in the assessment of cardiac output. 
  • Transvenous Right Greater Splanchnic Nerve Ablation in Heart Failure and Preserved Ejection Fraction: First-in-Human Study. 
  • Treatment Persistence of Renin-Angiotensin-Aldosterone-System Inhibitors Over Time in Heart Failure with Reduced Ejection Fraction. 
  • Treatment of HF in an Era of Multiple Therapies: Statement From the HF Collaboratory. 
  • Treatment of sleep-disordered breathing in heart failure impacts cardiac remodeling: Insights from the CAT-HF Trial. 
  • Treatment with 24 hour istaroxime infusion in patients hospitalised for acute heart failure: a randomised, placebo-controlled trial. 
  • Trends and Outcomes in Cardiac Arrest Among Heart Failure Admissions. 
  • Trends in Hospitalizations and Survival of Acute Decompensated Heart Failure in Four US Communities (2005-2014): ARIC Study Community Surveillance. 
  • Trends in Noncardiovascular Comorbidities Among Patients Hospitalized for Heart Failure: Insights From the Get With The Guidelines-Heart Failure Registry. 
  • Trends in Treatment for Patients Hospitalized with Heart Failure with Preserved Ejection Fraction Before and After Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT). 
  • Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes. 
  • Trends in the Use of Guideline-Directed Therapies Among Dialysis Patients Hospitalized With Systolic Heart Failure: Findings From the American Heart Association Get With The Guidelines-Heart Failure Program. 
  • Two-Dimensional Speckle Tracking Echocardiography Detects Subclinical Left Ventricular Systolic Dysfunction among Adult Survivors of Childhood, Adolescent, and Young Adult Cancer. 
  • Two-dimensional global longitudinal strain is superior to left ventricular ejection fraction in prediction of outcome in patients with left-sided infective endocarditis. 
  • Ultrafiltration in Acute Heart Failure: Implications of Ejection Fraction and Early Response to Treatment From CARRESS-HF. 
  • Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association. 
  • Update on aldosterone antagonists use in heart failure with reduced left ventricular ejection fraction. Heart Failure Society of America Guidelines Committee. 
  • Update on the Impact of Comorbidities on the Efficacy and Safety of Heart Failure Medications. 
  • Use of hydralazine-isosorbide dinitrate combination in African American and other race/ethnic group patients with heart failure and reduced left ventricular ejection fraction. 
  • Use of the 6-min walk distance to identify variations in treatment benefits from implantable cardioverter-defibrillator and amiodarone: results from the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial). 
  • Usefulness and Cost-Effectiveness of Universal Echocardiographic Contrast to Detect Left Ventricular Thrombus in Patients with Heart Failure and Reduced Ejection Fraction. 
  • Usefulness of ischemic response to mental stress in predicting silent myocardial ischemia during ambulatory monitoring. 
  • Usefulness of serial radionuclide angiography in predicting cardiac death after coronary artery bypass grafting and comparison with clinical and cardiac catheterization data. 
  • Utility of Growth Differentiation Factor-15, A Marker of Oxidative Stress and Inflammation, in Chronic Heart Failure: Insights From the HF-ACTION Study. 
  • Utility of the Cardiovascular Physical Examination and Impact of Spironolactone in Heart Failure With Preserved Ejection Fraction. 
  • Utilization of hospice and predicted mortality risk among older patients hospitalized with heart failure: findings from GWTG-HF. 
  • Validation of a novel modified wall motion score for estimation of left ventricular ejection fraction in ischemic and non-ischemic cardiomyopathy. 
  • Validation of pressure-volume data obtained in patients by initial transit radionuclide angiocardiography. 
  • Value of Cardiovascular Magnetic Resonance Imaging-Derived Baseline Left Ventricular Ejection Fraction and Volumes for Precise Risk Stratification of Patients With Ischemic Cardiomyopathy: Insights From the Surgical Treatment for Ischemic Heart Failure (STICH) Trial. 
  • Value of cardiovascular magnetic resonance stress perfusion testing for the detection of coronary artery disease in women. 
  • Value of clinician assessment of hemodynamics in advanced heart failure: the ESCAPE trial. 
  • Value of radionuclide angiography for predicting specific cardiac events after acute myocardial infarction. 
  • Valvular disease. 
  • Variability in Ejection Fraction Measured By Echocardiography, Gated Single-Photon Emission Computed Tomography, and Cardiac Magnetic Resonance in Patients With Coronary Artery Disease and Left Ventricular Dysfunction. 
  • Variables Measured During Cardiopulmonary Exercise Testing as Predictors of Mortality in Chronic Systolic Heart Failure. 
  • Variation in use and dosing escalation of renin angiotensin system, mineralocorticoid receptor antagonist, angiotensin receptor neprilysin inhibitor and beta-blocker therapies in heart failure and reduced ejection fraction: Association of comorbidities. 
  • Vectorcardiographic QRS area is associated with long-term outcome after cardiac resynchronization therapy. 
  • Ventricular Fibrillation Conversion Testing After Implantation of a Subcutaneous Implantable Cardioverter Defibrillator: Report From the National Cardiovascular Data Registry. 
  • Ventricular arrhythmia storms in postinfarction patients with implantable defibrillators for primary prevention indications: a MADIT-II substudy. 
  • Ventricular conduction and long-term heart failure outcomes and mortality in African Americans: insights from the Jackson Heart Study. 
  • Ventricular pacing or dual-chamber pacing for sinus-node dysfunction. 
  • Vericiguat and Health-Related Quality of Life in Patients With Heart Failure With Reduced Ejection Fraction: Insights From the VICTORIA Trial. 
  • Vericiguat for the treatment of heart failure with reduced ejection fraction. 
  • Vericiguat in Heart Failure with Reduced Ejection Fraction. Reply. 
  • Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. 
  • Vericiguat in patients with atrial fibrillation and heart failure with reduced ejection fraction: insights from the VICTORIA trial. 
  • Vericiguat in patients with coronary artery disease and heart failure with reduced ejection fraction. 
  • Vitamin D Levels in Black Americans and the Association With Left Ventricular Remodeling and Incident Heart Failure With Preserved Ejectin Fraction: The Jackson Heart Study. 
  • Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. 
  • What Is a Life Worth?: A Tribute to Dr. William Little, a Pioneer in the Understanding of Heart Failure With Preserved Ejection Fraction. 
  • What the dead can teach the living: systemic nature of heart failure with preserved ejection fraction. 
  • Which heart failure patients profit from natriuretic peptide guided therapy? A meta-analysis from individual patient data of randomized trials. 
  • Worsening Heart Failure Events in HFpEF: Underlying Biology Not Treatment Location. 
  • Worsening renal function and outcome in heart failure patients with reduced and preserved ejection fraction and the impact of angiotensin receptor blocker treatment: data from the CHARM-study programme. 
  • Worsening renal function in acute heart failure in the context of diuretic response. 
  • [Cardiac contractility modulation in heart failure with reduced ejection fraction treatment]. 
  • [Coronary bypass surgery remains to be effective in the treatment of patients with coronary artery disease and left ventricular dysfunction]. 
  • β1-Blockade increases maximal apnea duration in elite breath-hold divers. 
• 

  Keywords of People

  • Barker, Piers Christopher Andrew, Professor of Pediatrics, Pediatrics, Cardiology
  • Curtis, Lesley H., Professor in Population Health Sciences, Medicine, General Internal Medicine
  • Laskowitz, Daniel Todd, Professor of Neurology, Duke Science & Society
  • Milano, Carmelo Alessio, Joseph W. and Dorothy W. Beard Distinguished Professor of Experimental Surgery, Surgery, Cardiovascular and Thoracic Surgery
  • O'Connor, Christopher Michael, Adjunct Professor in the Department of Medicine, Medicine, Clinical Pharmacology
  • Pitt, Geoffrey Stuart, Adjunct Professor in the Department of Medicine, Medicine, Cardiology
  • Stinnett, Sandra Sue, Associate Professor of Biostatistics & Bioinformatics, Biostatistics & Bioinformatics